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1. INTRODUCTION 
 
1.1 NOVEL DRUG DELIVERY SYSTEM:  
 Historically, oral drug administration has been the predominant route for drug delivery 
due to the ease of administration, patient convenience and flexibility in formulations. However, it 
is a well accepted fact today that drug absorption throughout the GI tract is not uniform. Using 
currently utilized release technology, oral drug delivery for 12 or even 24 hours is possible for 
many drugs that are absorbed uniformly from GI tract. Nevertheless this approach is not suitable 
for a variety of important drugs characterized by narrow absorption window in the upper part of GI 
tract i.e. stomach and small intestine. 
 The design of oral controlled drug delivery systems (DDS) should be primarily aimed to 
achieve the more predictability and reproducibility to control the drug release, drug concentration 
in the target tissue and optimization of the therapeutic effect of a drug by controlling its release in 
the body with lower and less frequent dose. 
 The controlled release systems for oral use are mostly solid and based on dissolution or 
diffusion or a combination of both the mechanisms in the control of release rate of drug. 
Depending upon the manner of drug 
1.1.1. Classification  
A. Continuous release system: These systems release the drug for a prolonged period of 
time along the entire length of GIT with normal transit of the dosage form. The various 
systems under this category are:  
 
 Dissolution controlled release systems  
 Diffusion controlled release systems  
Introduction 
Department of Pharmaceutics, AVPC                                                           3 
 
 Dissolution and  diffusion controlled release systems  
 Ion-Exchange resins – drug complexes  
 slow dissolving salts and complexes  
 pH –dependent formulations  
 Osmotic pressure controlled systems  
 Hydrodynanic pressure controlled systems  
B. Delayed transit and continuous release system: These systems are designed to prolong 
their residence in the GIT along with their release. Often, the dosage is fabricated to 
retain in the stomach and hence the drug present therein should be stable at gastric PH. 
Systems included in this category are: 
 Altered density systems  
 Mucoadhesive systems  
 Size-based systems  
C. Delayed release systems: The design of such systems involve release of drug only at a 
specific site in the GIT.  
The drugs contained in such system have following category: 
 Destroyed in the stomach or by intestinal enzymes  
 Known to cause gastric distress  
 Absorbed from a specific intestinal site, or  
 Meant to exert local effect at a specific GI site.  
The two types of delayed release systems are: 
 Intestinal release systems  
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 Colonic release systems  
 Oral controlled release dosage forms have been developed for the past three decades due 
to their various benefit characteristics which includes. 
Table No.1: Advantages 
Benefit of oral controlled-release drug delivery systems 
Benefit Reason 
Therapeutic advantage Reduction in drug plasma level fluctuations; maintenance of a 
steady  plasma  level  of  the  drug  over  a  prolonged  period, 
ideally simulating an intravenous infusion of a drug 
Reduction  in adverse 
side effects and improvement in 
tolerability 
Drug plasma levels are maintained within a narrow therapeutic 
window  with  no  sharp  peaks  and  with  AUC  of  plasma 
concentration versus time comparable with total AUC from 
multiple dosing with immediate release dosage form. 
Patient comfort 
and compliance 
Oral drug delivery is the most common and convenient for 
patients,  and  a  reduction  in  dosing  frequency  enhances 
compliance. 
Reduction in health 
care cost 
The total cost of the controlled release product could be lower 
than the immediate release product. With reduction in side effects 
the overall expense in disease management also would be 
reduced. 
 
 Despite several advantages associated with controlled drug delivery system, there are 
number of disadvantages present with this type of drug delivery system. 
 
Advantages of Sustained drug delivery 
 As mentioned earlier, drug absorption from oral controlled release (CR) dosage forms is 
often limited by the short GRT available for absorption. 
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 However, HBS type dosage forms can retain in the stomach for several hours and 
therefore, significantly prolong the GRT of numerous drugs. . 
 These special dosage forms are light, relatively large in size, and do not easily pass 
through pylorus, which has an opening of approx. 0.1– 1.9 cms. 
Site specific drug delivery 
 A floating dosage form is a feasible approach especially for drugs which have limited 
absorption sites in upper small intestine. 
 The controlled, slow delivery of drug to the stomach provides sufficient local therapeutic 
levels and limits the systemic exposure to the drug. This reduces side effects that are caused by the 
drug in the blood circulation. In addition the prolonged gastric availability from a site directed 
delivery system may also reduce the dosing frequency. 
 The eradication of Helicobacter pylori requires the administration of various 
medicaments several times a day, which often results in poor patient compliance. More reliable 
therapy can be achieved by using GRDDS. Floating alginate beads have been used for the 
sustained release of Amoxycillin trihydrate. Thus, it can be expected that the topical delivery of 
antibiotic through a FDDS may result in complete removal of the organisms in the fundal area due 
to bactericidal drug levels being reached in this area, and might lead to better treatment of peptic 
ulcer. 
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Pharmacokinetic advantages 
 As sustained release systems, floating dosage forms offer various potential advantages. 
Drugs that have poor bioavailability because their absorption is limited to upper GI tract can be 
delivered efficiently thereby maximizing their absorption and improving their absolute 
bioavalabilities. 
 Floating dosage forms with SR characteristics can also be expected to reduce the 
variability in transit performance. In addition, it might provide a beneficial strategy for gastric and 
duodenal cancer treatment. 
 The concept of FDDS has also been utilized in the development of various anti-reflux 
formulations. Floating systems are particularly useful for acid soluble drugs, drugs poorly soluble 
or unstable in intestinal fluids, and those which may undergo abrupt changes in their pH dependent 
solubility due to food, age and disease states. 
Limitations 
 They require a sufficiently high level of fluids in the stomach for the drug delivery 
buoyancy, to float therein and to work efficiently.  
 Floating systems are not feasible for those drugs that have solubility or stability problems 
in gastric fluid.  
 Drugs such as Nifedipine, which is well absorbed along the entire GI tract and which 
undergoes significant first- pass metabolism, may not be desirable candidates for FDDS 
since the slow gastric emptying may lead to reduced systemic bioavailability.  
 Also there are limitations to the applicability of FDDS for drugs that are irritant to gastric 
mucosa.  
 
 
 
Introduction 
Department of Pharmaceutics, AVPC                                                           7 
 
Table No.2: Disadvantages 
Disadvantage of oral controlled-release drug delivery systems 
Disadvantage Reason 
Over dose 
There is always possibility of sudden release of the total 
dose administered i.e. dose dumping, which may result in toxic 
manifestations. 
Less  flexibility  in  dose 
adjustments 
The adjustment of dosage for controlled release dosage 
form is very difficult. The physician has less flexibility in 
adjusting the dosage regimens. 
Side effects 
Along with longer duration of action controlled release 
preparations   shows   long   duration   of   side   effects, 
especially if  the  patient  is  hypersensitive  to  the  given 
medication. 
Cost 
The cost of unit dose of controlled therapeutic system is 
higher than the conventional dosage forms. 
 
 To overcome these problems and improve the efficacy of oral administration, some 
recent studies have reported that controlled oral drug delivery system with prolonged gastric 
residence time, such as floating dosage system have been proved to be advantages. 
 A gastrointestinal drug delivery system can be made to float in the stomach by a gelling 
process of hydrocolloid materials or by incorporating a floatation chamber with vaccum or gas. In 
this way bulk density less than that of gastric fluid is produced. However, most of the devices 
generating gas or gelling need time to be floated and this parameter must be checked carefully in 
order to prevent the dosage form from transiting in to the small intestine along with food before 
floating in stomach. The floating system, more predictable drug release kinetics, less chances of 
localized mucosal damage, insignificant impairing of performance due to failure of a few units, co 
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administration of units with different release profile or obtaining incompatible substances, larger 
margin of safety against dosage form failure. 
1.2 GASTRO-RETENTIVE DOSAGE FORMS (GRDF):8-13 
 These are primarily controlled release drug delivery systems, which gets retained in the 
stomach for longer periods of time, thus helping in absorption of drug for the intended duration of 
time. Gastric retentive drug delivery devices can be useful for the spatial and temporal delivery of 
many drugs. 
 The gastric emptying time mainly depends upon the design of the dosage form and 
physiological state of the subject, which last from a few minutes to 12hrs. The average gastric 
emptying time in human is 2-3hrs through major absorption zone (stomach and upper part of the 
intestine), which leads to incomplete drug release from the DDS leading to diminished efficacy of 
the administered dose. So drugs which have stability problem, GRDF plays an important role. 
These considerations have led to the development of oral controlled release dosage forms 
possessing gastric retention capabilities. 
 GRDF will also greatly improve the pharmacotherapy of the stomach itself through local 
drug release leading to high drug concentrations at the gastric mucosa, which are sustained over a 
long period of time. 
 Finally, GRDF will be used as carriers for drugs with so called absorption windows: 
these substances are taken up only from very specific sites of the gastrointestinal mucosa, often in 
a proximal region of the small intestine. Need of gastro retention arises because of two reasons, 
viz. 
 
 To improve bioavailability of drugs such as cyclosporin, ciprofloxacin, ranitidine, 
metoprolol tartarate, cefuroxime axetil etc. which are mainly absorbed from upper 
part of GIT or get degraded in alkaline PH.  
 For local action in case of pathologies of stomach.  
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1.2.0 Anatomy and Physiology of Stomach:14  
1.2.1a)  Anatomy 
 The stomach is j- shaped organ located in the upper left hand portion of the abdomen just 
below the diaphragm. It occupies a portion of the epigastric and left hypochondriac region. The 
main function of the stomach is to store the food temporarily, grind it and then release it slowly 
into the duodenum. Due to its small surface area very little absorption takes place from the 
stomach. 
 
 
 
 
 
Figure No. 1: Anatomy of the stomach. 
The stomach has four main regions: 
1. Cardia 3. Body and 
2. Fundus 4. Pylorus 
 
 
 The main function of the fundus and body is storage, whereas that of cardia is mixing or 
grinding. The fundus adjusts the increased volume during eating by relaxation of the fundus 
muscle fibers. The fundus also exerts a steady pressure on the gastric contents pressing them 
towards the distal region, to pass through the pyloric sphincter into the small intestine. 
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1.2.1.b) Physiology 
 Various factors like absorption ability, presystemic clearance, gastric motility; 
gastrointestinal transit time and gastrointestinal emptying time will have an influence on the 
bioavailability of drug from the dosage form. 
Absorption ability 
 The absorption capability of various segments of gastrointestinal tract differs from each 
other. i.e. most of the absorption takes place in small intestine and lesser extent in colon and 
stomach. Unless drugs are absorbed equally in both the colon and in small intestine, the duration 
for most of the drugs is 3-8 hours. This will be the major limiting factor for sustained release and 
controlled release drug delivery systems. 
Presystemic clearance 
 Even if the drugs that can be absorbed equally well throughout the gastrointestinal tract, 
bioavailability is significantly reduced by the site-specific changes in presystemic clearance. 
Degradation of the drug is also carried out by hydrolysis in the stomach, enzymatic digestion, and 
metabolism in the brush border of the gut wall and by the microorganisms. 
 Such degradation may leads to high variation in plasma drug concentration and poor 
absorption of drug in to the systemic circulation. 
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Gastric motility 
 Gastric emptying occurs during fasting as well as fed states. During the fasting state an 
interdigestive series of electrical events take place, which cycles through stomach and intestine 
every 2 to 3 hours. This is called the interdigestive myloelectric cycle or migrating myloelectric 
cycle (MMC), which is further divided into 4 phases as described by Wilson and Washington. 
1. Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions.  
2. Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action and 
potential contractions. As the phase progresses the intensity and frequency also 
increases gradually.  
3. Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and regular 
contractions for short period. It is due to this wave that all the undigested material 
is swept  out  of the stomach  down to  the small  intestine.  It  is  also  known as  
the housekeeper wave. 
4. Phase IV lasts for 0 to 5 minutes and occurs between phases III and I of 2 
consecutive cycles.  
 After the ingestion of a mixed meal, the pattern of contractions changes from fasted to 
that of fed state. This is also known as digestive motility pattern and comprises continuous 
contractions as in phase II of fasted state. These contractions result in reducing the size of food 
particles (to less than 1 mm), which are propelled toward the pylorus in a suspension form. During 
the fed state onset of MMC is delayed resulting in slowdown of gastric emptying rate. 
Scintigraphic studies determining gastric emptying rates revealed that orally administered 
controlled release dosage forms are subjected to basically two complication, that of short gastric 
residence time and unpredictable gastric emptying rate. 
 
Gastrointestinal Transit Time 
 Food content remains in each segment of the gastrointestinal tract for different periods of 
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time. The resident time for both liquid and solid foods in each segment of the gastrointestinal tract 
is as reported by park. 
Table No.3: Transit time of food in each segment of the gastrointestinal tract 
Segment Liquid Solid 
Stomach 10-30min 1-3 hours 
Duodenum <60sec <60 sec 
Jejunum and ileum 3 hours ± 1.5 hours 4 hours ± 1.5 hours 
Colon ------------- 20-50 hours 
 
 Since most of the drugs are absorbed from the upper part of intestine, the total effective 
time for the drug absorption is 3-8 hours. So one has to take most of the drugs 3-6 times a day. 
1.2.1 c)   Various factors affecting the gastric emptying time:15  
I.  State of the stomach: gastric emptying time depends upon the fed state of the 
stomach, which increases the gastric emptying time as compared to unfed state.  
II.  Circadian rhythms: which are increased in daytime and less during night, also 
affects the gastric retention time (GRT).  
III. Size of the dosage form: greater the energy content of the meal (carbohydrate and 
high fat content), longer the duration of emptying.  
IV.  Density of the oral dosage form: The density of the gastric fluid is reported to be 
1.2g/cm. The density of the dosage form should be less than this for the buoyancy 
so that it is retained in the stomach for longer period of time. 
V. Diseased state: State of the stomach also affects the environment for the dosage 
form as in case of ulcers, flatulence and spasms.  
VI. Drug therapy: Plays an impotent role in gastric emptying e.g. prokinetic drugs like 
cisapride and mosapride increase the gastric emptying time. 
VII. Age: Increase in age decreases the gastric motility thereby increasing the gastric 
emptying time. 
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VIII. Posture: It was seen that the supine posture on the right side showed better results 
than on the left side. 
1.2.1 d)   Criteria for selection of drug candidate for GRDF:15 
 The gastric retentive drug delivery systems are suitable for following types of drug 
therapy: 
  Absorption from upper GIT: Drugs have a particular site for maximum absorption 
e.g. ciprofloxacin, whose maximum absorption is in the stomach only. The 
absorption of metformin hydrochloride is confirmed to small intestine only and the 
conventional sustained release dosage forms may be poorly bioavailable since 
absorption appears to diminish when the dosage form pass in to large intestine.  
  Drugs having low PKa, which remains unionized in stomach for better absorption.  
  Drugs having reduced solubility at higher PH e.g. captopril and chlordiazepoxide 
and the bioavailability of drugs that get degraded in alkaline PH can be increased 
by formulating gastro-retentive dosage forms. e.g. doxifluridine, which  degrades 
in small intestine. 
  Local action as it is seen in the treatment of H. Pylori by amoxicillin and 
misoprostol for ulcers.  
  To minimize gastric irritation which may be caused by sudden increase of drug 
concentration in the stomach. e.g. NSAIDs.  
  Improve effectiveness of particular drugs. E.g. antibiotics in the colon tend to  
disturb the microflora causing overgrowth of microorganisms like Clostridium 
difficile causing colitis. 
1.3 GASTRO RETENTIVE DRUG DELIVERY SYSTEM:1(b),15,16 
 Oral drug delivery is the most desirable and preferred method of administering 
therapeutic agents for their systemic effects. Oral medication is generally considered as the first 
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avenue investigated in the development of pharmaceutical formulations because of patient 
acceptance, convenience in administration and cost effective manufacturing processes. Oral route 
offers an attractive approach of drug targeting at the specific site within GI tract for certain types 
of drug. 
Requirements for gastro retention 
 From the discussion of the physiological factors in stomach, to achieve gastro retention, 
the dosage form must satisfy some requirements. One of the key issues is that the dosage form 
must be able to withstand the forces caused by peristaltic waves in the stomach and constant 
grinding and churning mechanisms. It must resist premature gastric emptying and once the purpose 
has been served, it should be removed from the stomach with ease 
Approaches to gastric retention 
 Over the last 3 decades, various approaches have been pursued to increase the retention 
of an oral dosage form in the stomach. These systems include: Bioadhesive systems, swelling and 
expanding systems, High density systems, Floating systems, Modified systems 1 . 
 
 
 
 
 
 
Figure No. 2   Approaches to gastric retention 
Floating Drug Delivery Systems 
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 The concept of FDDS was described in the literature as early as 1962. Floating drug 
delivery systems (FDDS) have a bulk density less than gastric fluids and so remain buoyant in the 
stomach without affecting the gastric emptying rate for a prolonged period of time. 
 While the system is floating on the gastric contents, the drug is released slowly at the 
desired rate from the system. After release of drug, the residual system is emptied from the 
stomach. This results in an increased GRT and a better control of fluctuations in plasma drug 
concentration 6 . 
 
 
 
 
Figure No. 3 The mechanism of floating systems 
 
Formulation of this device must comply with the following criteria 
1. It must have sufficient structure to form a cohesive gel barrier.  
2. It must maintain an overall specific gravity lower than that of gastric contents (1.004 – 
1.010). 
3.  It should dissolve slowly enough to serve as a drug reservoir. 
 A list of drugs used in the development of FDDS thus far is given in Table-4: 
 
 
Table. No.4 List of drugs explored for various floating dosage forms 6 
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Dosage Forms Drugs 
Microspheres  Aspirin, Ibuprofen, Tranilast 
Granules  Diclofenac sodium, Indomethacin, Prednisolone 
Capsules  Diazepam, Furosemide, L-Dopa and Benserazide 
Tablets / pills  Amoxycillin Trihydrate, Ampicillin, Diltiazem,  
p -Aminobenzoic acid, Riboflavin-5’-phosphate, 
Theophylline, Verapamil HCl 
 
 Based on the mechanism of buoyancy, two distinctly different technologies, i.e. 
noneffervescent and effervescent systems, have been utilized in the development of FDDS. 
1.3.1  Approaches to Gastric Retention: 
 A number of approaches have been used to increase the GRT of a dosage form in 
stomach by employing a variety of concepts. These include: 
 
a)  Floating Systems:17 
 Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids 
and thus remain buoyant in the stomach for a prolonged period of time, without affecting the 
gastric emptying rate. While the system is floating on the gastric contents, the drug is released 
slowly at a desired rate from the system. After the release of the drug, the residual system is 
emptied from the stomach. This results in an increase in the GRT and a better control of 
fluctuations in the plasma drug concentrations. Floating systems can be classified into two distinct 
categories, effervescent and non-effervescent systems. 
b)  Bio/Muco-adhesive Systems:18 
 Bio/Muco-adhesive systems are those which bind to the gastric epithelial surface or 
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mucin and serve as a potential means of extending the GRT of drug delivery system (DDS) in the 
stomach. 
 The surface epithelial adhesive properties of mucin have been well recognized and 
applied to the development of GRDS based on bio/muco-adhesive polymers. The ability to provide 
adhesion of a drug (or a delivery system) to the GI wall provides a longer residence time in a 
particular organ site, thereby producing an improved effect in terms of local action or systemic 
effect. 
 Binding of polymers to the mucin/epithelial surface can be divided into three broad 
categories: 
1. Hydration-mediated adhesion.  
2. Bonding-mediated adhesion.  
3. Receptor-mediated adhesion.  
 
 
c)  Swelling and Expanding Systems: 
 These are the dosage forms, which after swallowing; swell to an extent that prevents their 
exit from the pylorus. As a result, the dosage form is retained in the stomach for a longer. These 
systems may be named as “plug type system” since they exhibit the tendency to remain logged at 
the pyloric sphincter if that exceed a diameter of approximately 12-18 mm in their expanded state. 
Such polymeric matrices remain in the gastric cavity for several hours even in the fed state. 
 A balance between the extent and duration of swelling is maintained by the degree of 
cross-linking between the polymeric chains. A high degree of cross-linking retards the swelling 
ability and maintains its physical integrity for prolonged period. 
d)  High Density Systems 
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 These systems with a density of about 3 g/cm3 are retained in the rugae of the stomach 
and are capable of withstanding its peristaltic movements. A density of 2.6-2.8 g/cm3 acts as a 
threshold value after which systems can be retained in the lower part of the stomach. High-density 
formulations include coated pellets. Coating is done by heavy inert materials such as barium 
sulphate, zinc oxide, titanium dioxide, and iron powder. 
e)  Incorporation of Passage Delaying Food Agents 
 Food excipients like fatty acids e.g. salts of myristic acid change and modify the pattern 
of the stomach to a fed state, thereby decreasing gastric emptying rate and permitting considerable 
prolongation of release. The delay in the gastric emptying after meals rich in fats is largely caused 
by saturated fatty acids with chain length of C10-C14. 
 
 
f)  Ion Exchange Resins:19 
 A coated ion exchange resin bead formulation has been shown to have gastric retentive 
properties, which was loaded with bicarbonates. Ion exchange resins are loaded with bicarbonate 
and a negatively charged drug is bound to the resin. The resultant beads were then encapsulated in 
a semi-permeable membrane to overcome the rapid loss of carbon dioxide. Upon arrival in the 
acidic environment of the stomach, an exchange of chloride and bicarbonate ions take place, as a 
result of this reaction carbon dioxide was released and trapped in the membrane thereby carrying 
beads towards the top of gastric content and producing a floating layer of resin beads in contrast to 
the uncoated beads, which will sink quickly. 
g)  Osmotic Regulated Systems 
 It is comprised of an osmotic pressure controlled drug delivery device and an inflatable 
floating support in a bioerodible capsule. In the stomach the capsule quickly disintegrates to 
release the intragastric osmotically controlled drug delivery device. The nflatable support inside 
forms a deformable hollow polymeric bag that contains a liquid that gasifies at body temperature 
to inflate the bag. The osmotic controlled drug delivery device consists of two components, drug 
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reservoir compartment and osmotically active compartment. 
1.3.2  Types of Floating Drug Delivery Systems (FDDS):20-21 
 Based on the mechanism of buoyancy, two distinctly different technologies have been 
utilized in the development of FDDS, which are: 
A. Effervescent System  
B. Non- Effervescent System A. Effervescent System:  
 Effervescent systems include use of gas generating agents, carbonates (sodium 
bicarbonate) and other organic acid (citric acid and tartaric acid) to produce carbon dioxide (CO2) 
gas, thus reducing the density of the system and making it to float on the gastric fluid. These 
effervescent systems further classified into two types. 
I. Gas Generating Systems 
1. Intra Gastric Single Layer Floating Tablet or Hydrodynamically Balanced System 
(HBS)  
 
 
 
 
 
 
 
Figure No. 4: hydrodynamically balanced system 
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 These are formulated by mixing the CO2 generating agents and the drug within the 
matrix tablet (Fig. 4). These have a bulk density lower than gastric fluids and therefore remain 
floating in the stomach unflattering the gastric emptying rate for a prolonged period. The drug is 
slowly released at a desired rate from the floating system and after the complete release the 
residual system is expelled from the stomach. This leads to an increase in the GRT and a better 
control over fluctuations in plasma drug concentration. 
2.  Intra Gastric Bilayered Floating Tablets 
 These are also compressed tablet and contains two layers for: 
i) Immediate release layer and   ii) Sustained release layer (Fig. 5). 
 
 
 
 
 
 
 
 
Figure No. 5: Intra Gastric Bilayer Floating Tablet. 3. Multiple Unit type floating pills: 
 These systems consist of sustained release pills as „seeds’ surrounded by double layers. 
The inner layer consists of effervescent agents while the outer layer is of swellable membrane 
layer. When the system is immersed in dissolution medium at body temperature it sinks at once 
and then forms swollen pill like balloon and float as the density decreases (Fig. 6&7). 
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Figure No. 6
A multi-unit type oral floating
dosage system
 
A. Penetration of water 
B. Generation of CO
C. Dissolution of drug 
II.  Volatile Liquid / Vacuum Containing Systems
1.  Intragastric Floating Gastrointestinal Drug Delivery System:
 These system can be made to float in the stomach because of floatation chamber, which 
may be a vacuum or filled with air or a harmless gas, while drug reservoir is encapsulated inside a 
microporus compartment (Fig. 8).
 
 
 
 
 
                                                
 Figure No. 7 
 Stages of floating mechanism
 
 
 
2 and floating  
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Figure No. 8: Intra Gastric Floating Gastrointestinal Drug Delivery Device 
2.  Inflatable Gastrointestinal Delivery Systems 
 In these systems an inflatable chamber is incorporated, which contains liquid that 
gasifies at body temperature to cause the chamber to inflate in the stomach. These systems are 
fabricated by loading the inflatable chamber with a drug reservoir, which can be a drug 
impregnated polymeric matrix, then encapsulated in a gelatin capsule. After oral administration the 
capsule dissolves to release the drug reservoir together with the inflatable 
 
chamber. The inflatable chamber automatically inflates and retains the drug reservoir compartment 
in floating position. The drug continuously released from the reservoir into the gastric fluid (Fig. 
9). 
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Figure No. 9: Inflatable Gastrointestinal Delivery System
3.  Intragastric Osmotically Controlled Drug Delivery
 It is comprised of an osmotic pressure controlled drug delivery device and an inflatable 
floating support in a biodegradable capsule. In the stomach capsule quickly disintegrates to release 
the intragastric osmotically controlled drug delivery dev
deformable hollow polymeric bag that contains a liquid that gasifies at body temperature to inflate 
the bag. The osmotic pressure controlled drug delivery device consists of two components; drug 
reservoir compartment and an osmotically active compartment.
 The drug reservoir compartment is enclosed by a pressure responsive collapsible bag, 
which is impermeable to vapour and liquid and has a drug delivery orifice. The osmotically active 
compartment contains an osmot
In the stomach, the water in the GI fluid is continuously absorbed through the semipermeable 
membrane into osmotically active compartment to dissolve the osmotically active salt. An osmotic
pressure is thus created which acts on the collapsible bag and turns in forces the drug reservoir 
compartment to reduce its volume and activate the drug reservoir compartment to reduce its 
volume and activate the drug release in solution form through the 
 The floating support is also made to contain a bioerodible plug that erodes after a 
predetermined time to deflate the support. The deflated drug delivery system is then emptied from 
the stomach (Fig. 10). 
 
 
 
 
 
                                                
 System 
ice. The inflatable support inside forms a 
 
ically active salt and is enclosed within a semipermeable housing. 
delivery orifice.
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Figure No. 10: Intragastric Osmotically Controlled Drug Delivery System 
B.  Non Effervescent Systems: 
 The Non effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non-effervescent 
FDDS are gel forming or highly swellable cellulose type hydrocolloids, polysaccharides and 
matrix forming materials such as polycarbonates, polyacrylates, polymethacrylates, polystyrenes 
etc. and bioadhesive polymer such as chitosan and carbopol. 
The various types of these systems are: 
1.  Single Layer Floating Tablets:24-25 
 They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, which 
swells in contact with gastric fluid and maintain bulk density of less than unity. The air trapped by 
the swollen polymer confers buoyancy to these dosage forms. 
2.  Alginate Beads:26 
 Multi unit floating dosage forms were developed from freeze-dried calcium alginate. 
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping a sodium alginate 
solution into aqueous solution of calcium chloride, causing precipitation of calcium alginate 
leading to formation of porous system, which can maintain a floating force for over 12 hours. 
These floating beads gave a prolonged residence time of more than 5.5 hour. 
3.  Hollow Microspheres: 
 Multiple-unit hollow microspheres by emulsion solvent diffusion technique were 
prepared with Drug and acrylic polymer. These were dissolved in an ethanol-dichloromethane 
mixture, and poured into an aqueous solution of PVA with stirring to form emulsion droplets. The 
rate of drug release in micro balloons was controlled by changing the polymer to drug ratio. 
Microballoons were floatable in vitro for 12 hours when immersed in aqueous media. 
Radiographical studies proved that microballoons orally administered to humans were dispersed in 
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the upper part of stomach and retained there for 3 hours against peristaltic movements. 
1.4.1  Advantages of FDDS:15 
1. Drugs that act locally in the stomach e.g., Antacids, Antibiotics for microbial 
based ulcers, etc.  
2. Drugs that are absorbed primarily in the stomach e.g., Albuterol.  
3. Drugs that are poorly soluble in alkaline pH.  
4. Drugs that have a narrow window for absorption. i.e., Drugs that are absorbed 
mainly from the proximal part of small intestine. e.g., Riboflavin, Levodopa, p-
amino benzoic acid.  
5. Drugs that are absorbed rapidly from the GI tract. e.g., Amoxicillin.  
6. Drugs that degrade in the colon. e.g., Captopril, Metoprolol.  
1.4.2  Disadvantages of FDDS:15 
1. High Variability in gastric emptying time due to variations in emptying process.  
2. Drugs that cause irritation and lesions to gastric mucosa and unstable in gastric 
fluid cannot be formulated as FDDS.  
3. Drug with unpredictable bioavailability, minimum effective concentration is 
achieved slowly.  
4. Gastric retention is influenced by many factors such as gastric motility, pH, and 
presence of food. These factors are never constant and hence the buoyancy cannot 
be predicted.  
1.4.3 Application of FDDS:15  
1.   For treating local inflammation and stomach ulcers.  
2. For treating H. Pylori associated ulcers.  
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3. In chronic diseases associated with frequent medication and prolonged medication, 
FDDS can be promising drug delivery system.  
1.5 MATRIX SYSTEMS:1,27-30  
 A matrix is a uniform mixture of drug and excipients. e.g. polymer that is 
homogeneously fixed in solid dosage form. 
 The drug substance, which has a solubility S gm /cm3 in the dissolution medium, is 
dispersed in the matrix which is insoluble in the dissolution medium, is dispersed in the matrix 
which is insoluble in the dissolution medium. The concentration of drug in the matrix is „A’ gm / 
cm3. The matrix is porous, with a porosity of ‘Є’ and diffusion coefficient of  „Dm’. The drug 
release from such system can be described by dQ/dt = 2SDmAt. Liquid will intrude from the bulk 
liquid. The rate and extent of intrusion will follow the following equation: 
 
2
8
dL Qr q
dt L L
−
= = −
η
 ........ (1) 
 Where, L is the length of the intrusion at time t, r is the average radius of the pores, is the 
viscosity of the liquid and Q is a constant21. 
 
Figure No. 11: Dissolution of drug from a solid matrix 
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1.5.1 Hydrophillic Matrix System 
 A hydrophilic matrix controlled release system is a dynamic system composed of 
polymer wetting, polymer hydration and polymer dissolution. At the same time other soluble 
excipients or drug will also wet, dissolve and diffuse out of the matrix while insoluble materials 
will be hold in place until the surrounding polymer/ excipients / drug complex erodes or dissolves 
away. 
 
 The main principle is that a water-soluble binder, present throughout the tablet, partially 
hydrates on the outer tablet “sink” to form a gel layer. Throughout the life of ingested tablet the 
rate of drug diffusion (if soluble) out of the wet gel and the rate of tablet erosion control the overall 
dissolution rate and drug availability. 
 
 
 
 
 
 
 
Figure No. 12 : Matrix System 
1.5.2 Matrix Type31 
 The most common controlled delivery system has been the matrix type such as tablets 
and granules, where the drug is uniformly dissolved or dispersed through out the polymer, because 
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of its effectiveness, low cost, ease of manufacturing and prolonged delivery time period. 
 Hydrophilic polymers are becoming more popular in formulating oral controlled release 
tablets, it is well documented that the dissolution curve of drug release from a hydrophilic matrix 
shows a typical time dependent profile. The release of a dissolved drug inherently follows near 
first order diffusion either an initially high release rate, due to the dissolution of the drug present at 
the surface of the matrix followed by a rapidly declining drug release rate. The enhanced release 
rate observed at the beginning for the short time of release process is known as “burst effect” and 
is many a time undesirable since it may, have  negative therapeutic consequences. After this burst 
effect, hydration and consequent swelling and/or erosion of related polymer occur. These 
phenomenon’s control the release process but with time, the diffusion path length increases and 
saturation effect is attained, resulting in a progressively slow release rate during the end of 
dissolution span. 
 
 
 
 
 
Figure No. 13 : Schematic showing the burst effect in a zero-order 
Drug delivery system 
 In many controlled release formulations immediately upon placement in release medium, 
an initial large bolus of drug is release medium; an initial large bolus of drug is released before the 
release rate reaches a stable profile. This phenomenon is referred to as 
burst release 
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1.5.3. Cause of burst release  
1) Processing conditions  
2) Surface characteristics of host material  
3) Sample geometry  
4) Host and drug interaction (surface adsorption)  
5) Morphology and porous structure of dry material.  
1.5.4. Prevention of burst release  
 Several advanced technologies to avoid burst include; 
a)  Surface extraction of active agent 
 Approaches have been taken to reduce the initial burst, such as extracting the drug 
formulation for a short period of time in vitro before using them in-vivo application. Burst effect is 
reduced because drug is removed from the outer layers of controlled release devices. E.g. Lee 
showed the effectiveness of surface extraction in reducing burst release of Oxprenolol HCl from P-
HEMA hydrogen. 
b)  Coated surface 
 It is another method which prevents burst release is surface modification by additional 
coating steps to provide an outer layer with no drug. Colombo and co-workers have done extensive 
work in understanding the influence of exposed surface area on drug release. They defined a 
dimensionless parameter so, the swelling area number as 
 
1
. .........(2)d
dAS
D dt
=
 
Where, dA/dt = rate of releasing area charge 
D = drug diffusion coefficient  
c) Drug loading distribution  
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 Non uniform drug loading, i.e. the increasing concentrations away from surface 
overcome the growing rubbery gel layer. This gel layer typically leads to diminishing release rates 
with time in uniformly loaded gels. 
d)  Polymer morphology and composition 
 The polymer microstructure and hydrophilic/hydrophobic interaction also play an 
important role in determining drug distribution profiles and release characteristics. 
e)  Surface modification 
 To prevent burst release from porous polymer structures caused by solvent evaporation 
during processing many methods have been attempted which are based on changing the surface 
characteristics of the devices. 
1.6 SWELLING CHARACTERISTICS OF POLYMER:2(a) 
 The Peppa’s plot is useful to determine whether the drug release from the matrix is 
controlled by swelling of the polymer or not. The Peppa’s equation is 
log Q= log (kt½) ----------- (3) 
log Q= log k + 0.5 log t ------------ (4) 
Where, Q = amount of drug release in time t per unit area 
 k = release constant. 
 If the slope of a plot of log Q Vs log t is exactly 0.5, then the drug release occurs by 
perfect diffusion obeying Higuchi’s and Fick’s law. If it is in the range of 0.5 – 1, then the 
mechanism of release is diffusion and rate of diffusion is controlled by swelling of polymer. If it is 
bellow 0.5, then there is no swelling of matrix occur. 
1.7  DRUG RELEASE MECHANISM FROM MATRICES:32 
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 From time to time, various authors have proposed different types of drug release 
mechanisms from matrices. It has been proposed that drug release from the matrices usually 
implies water penetration in the matrix, hydration, swelling, diffusion of the dissolved drug 
(polymer hydro fusion), and / or the erosion of the gelatinous layer. However, it is worth mention 
that the release mechanism of a drug would depend on the dosage form selected, pH, and nature of 
the drug and of course, the polymer used.11 
a.  Zero order kinetics: 31,33 
 Drug dissolution from pharmaceutical dosage from that do not disaggregate and release 
the drug slowly (assuming that area does not change and no equilibrium conditions are obtained) 
can be represented by the following equation. 
W0 –Wt = Kt --------- (5) 
Where, W0 = initial amount of drug in the pharmaceutical dosage form, 
Wt  =  amount of drug in the pharmaceutical dosage form, 
t  =  time, 
K  =  Proportionality constant. 
 The pharmaceutical dosage form following this profile release the same amount of drug 
by unit of time and in this model can be explained by following equation: 
Qt = Q0 + K0t ---------------- (6)   
Where,   Qt  =  Drug dissolved in time t,  
Q0  =  Initial amount of drug in solution,  
K0  =  Zero order rate constant.  
  OR,   
  W = K.t (Xu and Sunada, 1995) --------- (7) 
 
Where  W is percentage drug release at time t,  
 K is the release rate constant. 
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b.  First order kinetics: 31,33 
 The application of this model to drug dissolution studies was first proposed by Gibaldi 
and Feldman (1967) and later by Wagner. The dissolution phenomena implies a surface action, as 
can be seen by Noyes – Whitney equation, 
( ).........(8)s
dc K C C
dt
= −
 
Where,   C  =  Concentration of solute in time t, 
 CS  =  Solubility in equilibrium at experience temperature. 
 k  = First order proportionality constant 
Hixson and Crowell adapted the above equation as 
( ).........(9)s
Dw KS C C
dt
= −
 
Where,  w  =  amount of solute in solution at time t, 
 S  =  Solid area accessible to dissolution. 
 log Qt  =  log Q0 + K1.t / 2.303 --------- (10) 
Where,   Qt  =  amount of drug release in time t, 
 Q0  =  initial amount of drug in solution, 
 K1  =  First order release constant. 
Above equation also represents this model. 
 The pharmaceutical dosage form following this dissolution profile, such as those 
containing water soluble drugs in porous matrices release drug in a way that is proportional to 
amount of drug remaining in its interior in such a way that amount of drug released by unit of time 
diminish. 
 OR,  In (100 – W) = In 100 – k t (Singla and Medrata, 1988; and 
Introduction 
Department of Pharmaceutics, AVPC                                                           33 
 
 Sunada 1995) ---------- (11) 
c.  Hixson Crowell Model or Hixson Crowell’s cube Root equation:31,34 
(Erosion Model) (Singla and Medirata, 1988) 
 Hixson Crowell recognizing that the particles regular area is proportional to the cubic 
root of its volume, derived an equation that can be described as 
 W01/3 – Wt1/3 = KSt ---------- (12) 
Where, W0  =  initial amount of drug, 
 Wt  =  remaining amount of drug, 
 KS  =  constant incorporating the surface volume relation, 
This can also be expressed as 
 (100 – w) 1/3 = 1001/3 – Kt ------------ (13) 
Where,  w  =  Percentage drug release at time t, 
 K  =  Release rate constant. 
d.  Higuchi Model / Higuchi’s square Root of time Equation (Diffusion model):31 
 Higuchi developed mathematical expressions for drugs particles dispersed in a uniform 
matrix behaving as diffusion media. To study the dissolution form a planar system having a 
homogeneous matrix, the relation obtained was 
ft    Q(2C  - CS )CS t  -------------- (14) 
 
Where,  Q  =  Amount of drug released in time t per unit area. 
Introduction 
Department of Pharmaceutics, AVPC                                                           34 
 
 C  =  Drug initial concentration 
 CS  =  drug solubility in matrix media 
 D  = Diffusivity of drug molecules in matrix substance. 
 
Figure No. 14: Drug theoretical concentration profile of a matrix system in Direct contact 
with a perfect sink release media 
 The solid line represents the variation of drug concentration in the pharmaceutical system 
after time t. To distance h, the concentration gradient will be constant, provided C>>Cs. The 
linearity order follows the Fick’s law. 
 (2 ).........(15)s sQ tDC C C= −  
 Relation is valid during all time except when the total depletion of drug in therapeutic 
system is achieved .Higuchi developed other models for release from heterogeneous matrix, when 
the drug concentration in matrix is lower than its solubility and the release occurs through pores in 
matrix, the obtained relation is: 
(2 ) .........(16)ts s
DEft Q C C C
T
= = − ε  
 
Where, Є = matrix porosity. 
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Or, 
 W =K t ½ ------------ (17) 
 W =  Percentage drug release at time t, 
 K = release constant. 
e.  Korsmeyer And Peppas Model:35-37 
 This equation is useful to study the diffusion / relaxation release of dosage form as well 
zero order release kinetics. The equation can be described as 
 
.........(18)ntM Kt
M
=
∞
 
Where,  t
M
M∞
= fraction of drug release in time t, 
 K = constant incorporating structural and geometric characteristics of  controlled 
release device.  
 n  =  diffusion release exponent indicative of release mechanism. 
 For release from swellable cylinders Ritger and Peppas have indicated, 
 n  =  0.45 for Fickian diffusion, 
n > 0 .45 and < 0.89 for anomalous diffusion or non Fickian diffusion (0.5 < n < 1) 
 n  =  0.89 for zero order release 
 n  =  1 or > 1 for super case 
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f.  Baker – Lonsdale Model:27,36,38 
 Baker developed model which described the drug controlled release from a spherical 
matrix, being represented by the following expression 
 
2 / 3
2
0 0
33 1 1 .........(19)
2
t t m msM M D C t
M M r C
∞ ∞
  
 − − − = 
   
 
 Mt =  drug release amount at time t,  Є =  Porosity of matrix 
 M∞ =  Drug released at ∞ Time, Df =  Diffusion coefficient.  
 Cms=  Drug solubility in matrix     
 This model is used to linearization of release data from microcapsules or microspheres 
g.  Hopfenberg Model:39 
 Mechanism of release from erodable matrix has been described by Hopfenberg. A simple 
expression describing release from erodable is: 
 
1 / 3
1 1 .......(20)tM kt
M
 
− = −  
 
Where, Mt  =  Mass of drug release at time t, 
k =  erosion constant,  
t =  time  
 Thus a plot of [Mt / M]1/3] versus the time will be linear, if the release of drug from the 
matrix is erosion controlled. 
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 This model assumes that rate limiting step of drug release is the erosion of matrix itself 
and that dependent diffusional resistance internal or external to eroding matrix do not influence it. 
1.8 MECHANISM OF DRUG RELEASE FROM MATRIX SYSTEM:38,39 
 When a hydrophilic matrix system containing a swellable glassy polymer comes in 
contact with an aqueous medium, the fall in glass transition temperature leads to an abrupt change 
from a glassy to a rubbery state, causing swelling of the polymer on the surface and formation of a 
hydrated gel. Drug release is controlled by this gel diffusional barrier and/or by surface erosion of 
the gel. Surface leaching of the drug can lead to an initial burst, especially with highly soluble 
drugs. 
 Hydration of individual polymer chains leads to expansion in their end to end distance 
and radius of gyration to a new solvated state due to lowering of the polymer transition 
temperature, a sharp distinction between glassy and rubbery region is observed and the matrix 
increases in volume because of swelling. 
 As water infiltrates deep in to the core, the thickness of the gel layer increases with 
simultaneous dissolution and erosion occurring at the outer layer due to complete hydration. 
 When the system is hydrated to the core, the drug concentration falls below its solubility 
value and the release rate of the drug begins to decline. A concurrent increase in the thickness of 
the barrier layer with time increases the diffusion path length, further reducing the release rate. 
Drug release kinetic associated with this gel layer dynamics, range initially from Fickian to 
anomalous (Non-Fickian) and subsequently from quasi-constant (near zero order) to constant. 
Matrices of highly molecular weight polymers rarely shows all three regimens (Fickian, Non-
Fickian and quasi-constant) of drug release because of a low chain disentanglement rate and 
insufficient external polymeric mass transfer. 
 
 Soluble drugs are primarily released by diffusion through aqueous filled porous network 
formed in the inert matrix former due to dissolution and erosion of the polymer from the surface. 
Far poorly soluble drugs dispersed in inert polymer systems erosion is the primarily release 
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mechanisms. 
 There are two major processes that control the drug release from swelling controlled 
matrix systems, these include: 
1. Ingress of aqueous medium into the matrix followed by a hydration, gelation or 
swelling and  
2. Matrix erosion.  
 Simultaneous occurrence of these processes leads to the formation of two fronts within 
the hydrating matrix, this are- a swelling front, at the junction of the unhydrated glassy matrix and 
the hydrated matrix and an eroding front where the polymer is completely hydrated. Thickness of 
the diffusion layer, i.e. the distance between the two fronts, depends on the relative rates at which 
the swelling and erosion occurs. 
 If the polymer gels slowly, solvent can penetrate deep into the glassy matrix, thus 
dissolving the drug; therefore, gel layer thickness and its stability are crucial in controlling drug 
release. Numbers of techniques have been used to study the swelling of matrix tablets and to 
characterize the gel layer and front movement such as, optical imaging, 1H- NMR, pulsed –filled 
gradient spin echo NMR, confocal laser scanning microscopy, cryogenic scanning electron 
microscopy and texture analysis. The gel layer thickness is determined by the relative position of 
the swelling and erosion front. 
1.9.  ADVANTAGES OF HYDROPHILIC MATRIX SYSTEM:39- 
 A hydrophilic matrix system essentially consists of a drug dispersed in a water swelling 
viscous polymer. These systems offer a number of advantages over other sustained release 
technologies namely. 
1. Simplicity of formulation.  
2. High drug loading as high as 80 % is possible in many cases.  
3. The system is usually inexpensive as the rate-controlling agent is usually a GRAS 
(generally accepted as safe) food polysaccharides.  
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4. Number of matrix former is available allowing development of formulations that 
meet special needs and avoid patent infringement.  
5. The systems are eroded as they pass the GIT thus there are no accumulation of 
“Ghosts” or empty shells.  
6. As system depends on both diffusion and erosion for drug release, release is not 
totally dependent on GI motility.  
7. No specialized equipment is required which substantially reduces manufacturing 
costs.  
8. Offer easy scalability and process validation due to simple manufacturing 
processes. 
 The above listed advantages overshadow the undesirable property of reducing release 
rates with time. 
1.10.  FACTORS    INFLUENCING    DRUG    RELEASE    FROM MATRIX 
SYSTEMS:412,16,35 
 A number of formulation variables and properties of the rate controlling polymer and the 
drug itself can be altered to attain a desired release rate from a matrix system. The mechanism by 
which drug release is controlled in matrix tablets are dependent on many variables, these variables 
are summarized in figure. 
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Figure No. 15 : Summary of factors influencing release rate from Matrix systems 
 There are several commercial products available based on the research activity of 
floating drug delivery (table-5). 
Table.No. 5 Marketed Preparations of Floating Drug Delivery Systems59 
S. No Product Active Ingredient Reference No. 
1 Madopar Levodopa and benserzide 63 
2 Valrelease Diazepam 64 
3 Topalkan Aluminum magnesium antacid 65 
4 Almagate flatcoat Antacid 66 
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Table. No. 6. List of Drugs Formulated as Single and Multiple Unit Forms of Floating Drug 
Delivery Systems 
DOSAGE FORM DRUG 
• Tablets Chlorpheniraminemaleate4 
 Theophylline23 
 Furosemide31 
 Ciprofolxacin37 
 Pentoxyfillin40 
 Captopril44 
 Acetylsalicylicacid52 
 Nimodipine59 
 Amoxycillintrihydrate71 
 VerapamilHCl75 
 Isosorbidedinitrate76 
 Sotalol77 
 Atenolol89 
 Isosorbidemononitrate100 
 Acetaminophen102,103 
 Ampicillin104 
 Cinnarazine105 
 Diltiazem106 
 Florouracil107 
 Piretanide108 
 Prednisolone109 
 Riboflavin- 5′ Phosphate110 
• Capsules Nicardipine41 
 L-Dopaandbenserazide63 
 hlordiazepoxideHCl64 
 Furosemide84 
 Misoprostal86 
 Diazepam111 
 Propranlol112 
 Urodeoxycholic acid113 
• Microspheres Verapamil27 
 Aspirin,griseofulvin,andp-nitroaniline43 
 Ketoprofen49 
 Tranilast55 
 Iboprufen80 
 Terfenadine114 
• Granules Indomathacin71 
 Diclofenacsodium88 
 Prednisolone115 
• Films Drugdeliverydevice62 
 Cinnarizine106 
• Powders Several basic drugs56 
1.11. Antibiotics 
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 The word "antibiotics" comes from the Greek anti ("against") and bios ("life"). 
Antibiotics are drugs that either destroy bacteria or prevent their reproduction. Antibiotics that kill 
bacteria are called "bactericidal" and the ones that stop the growth of bacteria are called 
"bacteriostatic". 
 Since penicillin's introduction during the 1940s, scientists developed numerous other 
antibiotics. Today, over 100 different antibiotics are available. About 90% of antibiotics are made 
from living organisms such as bacteria, others are produced synthetically, either in whole or in 
part. 
Table No.7 Classification Of Antibiotics 
Class (chemical 
structure) Mechanism of action Examples 
B-lactam antibiotics 
Penicillins 
Cephalosporins 
Carbapenems 
Inhibit bacterial cell wall 
synthesis 
Penicillins 
Penicillin G 
Amoxicillin 
Flucloxacillin 
Cephalosporins 
Cefoxitin 
Cefotaxime 
Ceftriaxone 
Carbapenem 
Imipenem 
Macrolides Inhibit bacterial protein 
synthesis 
Erythromycin 
Azithromycin 
Clarithromycin 
Tetracyclines Inhibit bacterial protein 
synthesis 
Tetracycline 
Minocycline 
Doxycycline 
Lymecycline 
Fluoroquinolones Inhibit bacterial DNA synthesis Norfloxacin 
Ciprofloxacin 
Enoxacin 
Ofloxacin 
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Sulphonamides Blocks bacterial cell 
metabolism by inhibiting 
enzymes 
Co-trimoxazole 
Trimethoprim 
Aminoglycosides Inhibit bacterial protein 
synthesis 
Gentamicin 
Amikacin 
Imidazoles Inhibit bacterial DNA synthesis Metronidazole 
Peptides Inhibit bacterial cell wall 
synthesis 
Bacitracin 
Lincosamides Inhibit bacterial protein 
synthesis 
Clindamycin 
Lincomycin 
Other Inhibit bacterial protein 
synthesis 
Fusidic acid 
Mupirocin 
 
1.11.1  Cephalosporins 
 Cephalosporin compounds were first isolated from cultures of Cephalosporium 
acremonium from a sewer in Sardinia in 1948 by Italian scientist Giuseppe Brotzu. The first agent 
cephalothin (cefalotin) was launched by Eli Lilly in 1964. 
 Cephalosporins are used to treat a wide variety of bacterial infections, such as respiratory 
tract infections (pneumonia, strep throat, tonsillitis, and bronchitis), skin infections and urinary 
tract infections. They are sometimes given with other antibiotics. Cephalosporins are also 
commonly used for surgical prophylaxis - prevention of bacterial infection before, during, and 
after surgery. 
A)  Classification of Cephalosporins 
 Cephalosporins are grouped into "generations" based on their spectrum of antimicrobial 
activity. The first cephalosporins were designated first generation while later, more extended 
spectrum cephalosporins were classified as second generation cephalosporins. Each newer 
generation has significantly greater gram-negative antimicrobial properties than the preceding 
generation, in most cases with decreased activity against gram-positive organisms. Fourth 
generation cephalosporins, however, have true broad spectrum activity. 
a.  First generation 
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 First generation cephalosporins are moderate spectrum agents. They are effective 
alternatives for treating staphylococcal and streptococcal infections and therefore are alternatives 
for skin and soft-tissue infections, as well as for streptococcal pharyngitis. 
 The first generation cephalosporins are Cefadroxil, Cephalexin, Cephaloridine, 
Cephalothin, Cephapirin, Cefazolin, and Cephradine. Cefazolin is the most commonly used first 
generation cephalosporin. The others have similar efficacy to Cephalexin, but must be dosed more 
often, and are therefore not as commonly prescribed. 
b. Second generation 
 The second generation cephalosporins have a greater gram-negative spectrum while 
retaining some activity against gram-positive bacteria. They are useful agents for treating upper 
and lower respiratory tract infections, sinusitis and otitis media. These agents are also active 
against E. coli, Klebsiella and Proteus, which makes them potential alternatives for treating urinary 
tract infections caused by these organisms. 
 The second generation cephalosporins are Cefaclor, Cefoxitin, Cefprozil, Cefuroxime. 
c. Third generation 
 Third generation cephalosporins have a broad spectrum of activity and further increased 
activity against gram-negative organisms. Some members of this group (particularly those 
available in an oral formulation) have decreased activity against gram-positive organisms. The 
parenteral third generation cephalosporins (ceftriaxone and cefotaxime) have excellent activity 
against most strains of Streptococcus pneumoniae, including the vast majority of those with 
intermediate and high level resistance to penicillin. These agents also have activity against N. 
gonorrhoeae. Ceftazidime has useful antipseudomonal activity. 
 The third generation cephalosporins are Cefdinir, Cefixime, Cefpodoxime, Ceftibuten, 
Ceftriaxone, Cefotaxime. 
d. Fourth generation 
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 Fourth generation cephalosporins are extended spectrum agents with similar activity 
against gram-positive organisms as first generation cephalosporins. They also have a greater 
resistance to beta-lactamases than the third generation cephalosporins. Many can cross blood brain 
barrier and are effective in meningitis. 
 The fourth generation cephalosporins are Cefepime, Cefluprenam, Cefozopran, 
Cefpirome, Cefquinome. 
1.12.  RATIONALE BEHIND THE SELECTION OF CEFADROXIL AS FLOATING 
MATRIX SUSTAINED RELEASE TABLET 
 cefadroxil is acid stable and its half life is 1.5  hrs  
 Absorbed completed and rapidly from Gastro intestinal tract.  
 Density is less than one.  
 cefadroxil  have pka. 9.69  which is unionized in acidic medium.  
 GRDFs can be used as carrier for drugs with so-called absorption window. 
Example:  
 Antifungal,  
 Antiviral,  
 Antibiotic agents.  
 Sulphonamides, quinolones, cephalosporin's, aminoglycosides and tetracycline are taken 
up only from very specific sites of the GI mucosa
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2. LITERATURE REIVEW 
 Manoj N. Gambhire et al31 Floating matrix tablets of DTZ were 
developed to prolong gastric residence time and increase its bioavailability.. The 
tablets were prepared by direct compression technique, using polymers such as 
hydroxyl propyl methylcellulose (HPMC, Methocel K100M CR), Compritol 888 
ATO, Sodium bicarbonate.. A 32 factorial design was applied to systematically 
optimize the drug release profile.The amounts of Methocel K100M CR (X1) and 
Compritol 888 ATO (X2) were selected as independent variables. The time required 
for 50% (t50) and 85% (t85) drug dissolution were selected as dependent variables. 
The results of factorial design indicated that a high level of both Methocel K100M 
CR (X1) and Compritol 888 ATO (X2) favors the preparation of floating controlled 
release of DTZ tablets. 
 AV Mayavanshi* and SS Gajjar21 Floating drug delivery systems to 
increase gastric retention of drugs Gastric emptying is a complex process and makes 
in vivo performance of the drug delivery systems uncertain. In order to avoid this 
variability, efforts have been made to increase the retention time of the drug-delivery 
systems for more than 12 hours. The floating or hydrodynamically controlled drug 
delivery systems are useful in such application. The present review addresses briefly 
about the floating drug delivery systems. 
 Ramesh.R.Putheti1 Mahesh.C.Patil22 Pharmaceutical Formulation and 
development of Floating and Swellable sustained drug delivery systems: .The 
purpose of this review on floating and swellable drug delivery systems is tocompile 
the recent literature with special focus on the principal mechanism offloatation to 
achieve gastric retention. The review also aims to discuss variousparameters 
affecting the behavior of floating and swelling multiparticulate in oraldosage form 
summarizes the in vitro techniques, in vivo studies to evaluate theperformance and 
application of floating and swellable systems, andapplications ofthese systems. 
These systems are useful to several problems encountered during the development of 
a pharmaceutical dosage form. From the formulation andtechnological point of 
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view, the floating and swellable drug delivery systems areconsiderably easy and 
logical approach. An attempt has been made in this reviewarticleto introduce the 
scientists to the current technological developments in floating and swellable drug 
delivery system. 
 Samyuktha  rani  b.1,  vedha  hari  b.n.*1,  brahma  reddy.a.1,  punitha.  
S.2, Parimala devi1, victor rajamanickam1 The recent developments on gastric 
floating Drug delivery systems. The purpose of this review on Floating Drug 
Delivery Systems (FDDS) was to compile the recent literature with special focus on 
the principal mechanism of floatation to achieve gastric retention. The 
recentdevelopments of FDDS including the physiological and formulation ariables 
which affect the gastric retention and approaches to design single-unit and multiple 
unit floating systems, their classification and formulation aspects are covered in 
detail. This review also summarizes various sophisticated and modern in-vitro 
techniques to evaluate the performance, advantages and applications of floating 
systems. These systems are useful to avoid all the problems that are encountered 
during the development of a pharmaceutical dosage forms. Thus floating drug 
delivery systems seems to be the promising delivery systems for control release of 
drugs. 
 Shailesh T. Prajapati et al.,23 Studied to develop an optimized gastric 
floating drug delivery system (GFDDS) containing domperidone. Box-Behnken 
design was employed in formulating the GFDDS with three polymers: 
hydroxypropyl methylcellulose K4M (HPMC K4M) (X1), Carbopol 934P (X2) and 
sodium alginate (X3), as independent variables. Floating lag time (FLT), total 
floating time (TFT), time required to release 50% of the drug (t50) and diffusion 
exponent (n) were selected as dependent variables, dissolution data obtained was 
fitted to the power law and floating profiles were analyzed. HPMC loading was 
found to be significant for floating propertiesand desired release. 
 
 
Literature Review 
 
Department of Pharmaceutics, AVPC                                                         49 
 
 D R Chisholm, R G DeRegis, and D A Behr24 Therapeutic efficacy of 
cefadroxil and cephalexin for pneumonia in a rat test model. The therapeutic 
efficacies of cefadroxil and cephalexin were compared in a Streptococcus pyogenes-
induced lung infection in rats. Although MICs, rates of in vitro killing in rat serum, 
and antibiotic serum levels after oral administration were similar for both drugs, 
cefadroxil was about eight times more effective than cephalexin in reducing the 
number of viable streptococci at the site of infection. This excellent in vivo 
bactericidal activity of cefadroxil in lung tissue and bronchial secretions was 
reflected in the 50% protective dose (PD50) after single or multiple oral treatments. 
A single treatment given 24 h after infection resulted in a PD50 of 2.8 mg of 
cefadroxil per kg, compared with 21 mg of cephalexin per kg. When treatment was 
administered three times, at 24, 27, and 30 h postinfection, the PD50s of cefadroxil 
and cephalexin were 0.7 and 8.0 mg/kg, respectively. In infected animals, treated 24 
h postinfection, the area under the lung tissue concentration versus time curve for 
cefadroxil was significantly greater than that of cephalexin. This difference in 
pharmacokinetic behavior may account, at least in part, for the superior therapeutic 
results obtained with cefadroxil in this experimental pulmonary infection. 
 Shawky Tous S. et al.,25 Developed Nitrofurantoin floating matrix tablets, 
Hydroxypropyl methylcellulose (HPMC) of different viscosity grades together with 
a gas generating agent (sodium bicarbonate) and other optional additives were 
examined to optimize the floating characters of the prepared tablets. The in vitro 
study of the floating behavior in simulated gastric fluid (pH 1.2, enzyme free) at 
37°C showed that tablets eroded upon contact with the release medium. The results 
also showed that tablet composition had profound effect on the floating behavior and 
drug release. All formulations showed suitable floating lag time (20 s), with duration 
of floating more than 8 h. The drug release from those tablets was sustained over 8 h. 
 Leopoldo Villafuerte-Robles et al.,26 Developed a controlled release 
formulation of Captopril, floating tablets, and studied the in vitro sustained release 
of captoprill varying the proportions of Metolose SH400 and bicarbonate, Floating 
behavior studying at two different compaction pressures at (155Mpa&165Mpa). 
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Other studied variables include the kinetics of the hydration volume, the matrices 
floating time and the matrix density. The results show that matrices compacted at 55 
MPa float in the dissolution medium for more than 8 h while those compacted at 165 
MPa. The matrix density is lower when compacted at 155 MPa. The drug release 
constant (k) decreases and the exponent indicative of the release mechanism (n) 
increases with increasing polymer contents. 
 Subhabrata Ray et al.,36 Formulated Metformin hydrochloride floating 
microspheres. by non-aqueous emulsification solvent evaporation technique using 
Ethyl cellulose as the rate controlling polymer and Evaluation of Floating Drug 
Delivery System (FDDS) in vitro, prediction of the release, and optimization of 
floatation and drug release pattern to match target release profile was investigated in 
vitro floatation and release studies. floating time (> 8 hr) and the best results were 
obtained at the ratio of drug: polymer: solvent (250:750:12 and 250:146.45:9 [mg : 
mg : ml]), when both the batches were mixed in equal proportions. 
 Javed Ali et al.,27 Formulated hydro dynamically balanced system for 
celecoxib as single-unit floating capsules. Various grades of low-density polymers 
were used. The capsules were prepared by physical blending of celecoxib and the 
polymer in varying ratios. The formulation was optimized on the basis of in vitro 
buoyancy and in vitro release in citrate phosphate buffer pH 3.0 (with 1% sodium 
lauryl sulfate). Capsules prepared with polyethylene oxide 60K and Eudragit RL100 
gave the best in vitro percentage release and were used as the optimized formulation. 
By fitting the data into zero-order, first-order, and Higuchi models, we concluded 
that the release followed zero-order kinetics. 
 V.s Belgamwar28 Floating bioadhesive drug delivery system using 
effervescent agents 2009 Asian journal of pharmaceutics The results also showed 
that tablet composition had profound effect on the floating behavior and drug 
release. All formulations showed suitable floating lag time (20 s), with duration of 
floating more than 8 h. The drug release from those tablets was sustained over 8 h. 
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 Arvind Kumar Bansal et al., 49Studied, regional variability in different 
segments of the gastrointestinal tra vis-a-vis solubility and metabolism were 
investigated, and the results indicated potential for a gastro retentive (GR) dosage 
form. Suitability of a GR dosage from for CP and finally in vivo efficacy were 
investigated. Thereafter, an effervescent floating GR dosage form was developed for 
CP and evaluated in rats. The GR dosage form improved the oral bioavailability of 
CP significantly by about 75%, hence providing a proof-of-concept. The Tmax value 
increased to 1.43±0.24 h from 0.91 ±0.23 h of pure drug, while Cmax values of 
4735x802 ng ml and 3094 + 567 ng ml were obtained for the GR dosage form and 
pure drug respectively. 
 D.M. Patel et al.,30 Developed carbamazepine Floating tablets using melt 
granulation technique. Bees wax, Hydroxy propyl Methyl cellulose, sodium 
bicarbonate and ethyl cellulose were used as matrixing agent, gas-generating agent 
and floating enhancer, respectively. A simplex lattice design was applied to 
investigate the formulation variables i.e. amount of hydroxypropyl methylcellulose 
(X1), ethyl cellulose (X2) and sodium bicarbonate (X3). The floating lag time (Flag), 
time required for 50% (t50) and 80% drug dissolution (t80) were taken as responses. 
Results of multiple regression analysis indicated that, low level of X1, and X2 and 
high level of X3 should be used to manufacture the tablet formulation with desired 
in-vitro floating time and dissolution. 
 Mukesh C. Gohel et al.,31 Gastroretentive tablets of rifampicin (150 mg) 
were prepared by the wet granulation method using hydroxypropyl methylcellulose, 
calcium carbonate, and polyethylene glycol 4000. to minimize degradation of 
rilampicin in acidic medium and to modulate the release of rifampicin in the 
stomach and isoniazid in the intestine.. The in vitro drug release and in vitro drug 
degradation studies were performed. Rifampicin was released over 4 hours by zero-
order kinetics from the novel dosage form. More than 90% of isoniazid was released 
in alkaline medium in 30 minutes 
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 Anand Kumar Srivastava et al.,32 Prepared and Evaluated Cimetidine 
floating microspheres. were prepared by the solvent evaporation method using 
polymers hydroxypropylmethyl cellulose and ethyl cellulose. The shape and surface 
morphology of prepared microspheres were characterized by optical and scanning 
electron microscopy, respectively. In vitro drug release studies were performed and 
drug release kinetics was evaluated using the linear regression method . Microsphere 
float up to 8 h and buoyant up to10 h. 
 Shashi Kiran Mishra et al.,33 Formulated gastro retentive controlled release 
system of loratadine was to increase the residence time in stomach and to modulate 
the release behaviour of the drug. Oil entrapped floating microbeads prepared by the 
emulsion gelation method were optimized by 23 factorial design and a polymer ratio 
of 2.5:1.5 (pectin/sodium alginate) by mass, 15% (m/V) of oil (mineral oil or castor 
oil) and 0.45 mol L–1 calcium chloride solution as the optimized processing 
conditions for the desired buoyancy and physical stability. In vitro drug release in 
the fed state conditions demonstrated sustained release of loratadine for 8 h, which 
best fitted the Peppas model with n < 0.45. The ethyl cellulose coating on 
microbeads optimized by22 factorial design resulted in a controlled release 
formulation of loratadine that provided zero-order release for 8 h. 
 C. Narendra et al.,34 Studied A23 factorial design was employed in 
formulating the GFDDS Of Metoprolol succinate with total polymer content-to drug 
ratio (X1), polymer-to-polymer ratio (X2), and different viscosity grades of 
hydroxypropyl methyl cellulose (HPMC) (X3) as independent variables. Four 
dependent variables were considered: percentage of MT release at 8 hours, T50%, 
diffusion coefficient, and floating time. The main effect and interaction terms were 
quantitatively evaluated using a mathematical model. The results indicate that X1 
and X2 significantly affected the floating time and release properties, but the effect 
of different viscosity grades of HPMC (K4M and K10M) was non significant. 
Regression analysis and numerical optimization were performed to identify the best 
formulation. 
 D. More et al.,35 Prepared a Gastroretentive drug delivery system (bilayer 
tablets and capsules) of Rosiglitazone Maleate, because its maximum solubility was 
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in 0.1 N HCL i.e. (pH 1.2: 11.8035 mg/ml) and in differentbuffer it was (pH 5.8: 
3.7025 mg/ml, pH 7.3: 3.5137 mg/ml, pH 10: 3.250 mg/ml). studied the effect of 
sodium bicarbonate, HPMC K 100 M, microcrystalline cellulose (MCC) and 
Dicalcium phosphate (DCP) on drug release profile, matrix integrity and 
floatingproperties of bilayer tablets were investigated. 
 Y. S. Tanwar et al.,36 Floating tablets of famotidine were prepared 
employing two different grades of methocel K100 and methocel K15M by 
effervescent technique; these grades of methocel were evaluated for their gel 
forming properties. Sodium bicarbonate was incorporated as a gas generating agent. 
The floating tablets were evaluated in vitro buoyancy and dissolution studies. The 
effect of citric acid on drug release profile and floating properties was investigated. 
The prepared tablets exhibited satisfactory physico-chemical characteristics. It was 
observed that the tablet remained buoyant for 6-10 hours. Decrease in the citric acid 
level increased the floating lag time but tablets floated for longer duration. 
 Brijesh S. Dave,1 Avani F. Amin,1 and Madhabhai M. Patel1 37 The 
purpose of this research was to prepare a gastroretentive drug delivery system of 
ranitidine hydrochloride. Guar gumxanthan gum, and hydroxypropyl 
methylcellulose were eval-uated for gel-forming properties. Sodium bicarbonate was 
incorporated as a gas-generating agent. The effects of citric acid and stearic acid on 
drug release profile and floating properties were investigated. The addition of stearic 
acid reduces the drug dissolution due to its hydrophobic nature. A 32 full factorial 
design was applied to systemically optimize the drug release profile. The amounts of 
citric acid anhydrous (X1) and stearic acid (X2) were selected as independent vari- 
ables. The times required for 50% (t50) and 80% drug disso-lution (t80), and the 
similarity factor f2 were selected as dependent variables. The results of the full 
factorial design indicated that a low amount of citric acid and a high amount of 
stearic acid favors sustained release of ranitidine hydrochloride from a 
gastroretentive formulation. A theoret- ical dissolution profile was generated using 
pharmacokinetic parameters of ranitidine hydrochloride. These studies indicate that 
the proper balance between a release rate enhancer and a release rate retardant can 
produce a drug dis- solution profile similar to a theoretical dissolution profile.
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3.  AIM & OBJECTIVE 
3.1  AIM 
• Cefadroxil is acid stable and it is used in the treatment of bacterial 
infections, some dose related side effects (nausea, abdominal pain, 
head ache, diarrhoea, chest pain, depression, burning sensation, 
mental disorders dizziness) are associated with conventional dosage 
form.  
• Normally conventional dosage form of Cefadroxil need twice or 
thrice daily which may lead to Non-compliance.  
• The aim is to minimize the above side effects and to reduce the 
frequency of dose. This can be achieved through Gastro retentive 
drug delivery system.  
3.2  OBJECTIVES 
 To prepare a Gastro retentive Drug Delivery System for cefadroxil in 
two different strength (125& 250 mg) by using different 
concentrations HPMC K100M.  
 To Evaluate the Physicochemical parameters, In-vitro drug release 
for 24 hours, swelling studies, Buoyancy studies (Buoyancy lag time 
and Floating duration time), Kinetics drug release and to find out the 
best formulation.  
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 4. PLAN OF WORK 
 
Preformulation Studies 
 Description and solubility of drug. 
 Predicting the   max and identification of pure drug. 
 FTIR studies (compatibility studies) 
Preparation of Standard curve 
 In Distilled water  
 In 0.1 HCL.  
Precompression parameters 
 Determination of angle of repose.  
 Determination of bulk and tapped density  
 Carr’s index.  
 Hauser ratio  
Formulation 
 To formulate floating tablets in Two different strength (125 & 250 mg) by 
using different concentrations HPMC k 100M (effervescent method) 
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Evaluation of floating tablets 
 Finding hardness,  
 Weight variation  
 Friability.  
 Thickness.  
 Assay ( UV spectrophotometric method & HPLC  method)  
 Dissolution Studies ( 0.1N HCL )  
 Swelling  index.  
• Buoyancy studies.  
• Buoyancy lag time  
 Floating duration time  
 Kinetics  Release Of Durg  
 Accelerated stability studies  
 ( Environmental test chamber) 
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5. DRUG PROFILE 
 
 Drug Name : Cefadroxil. 
 Generation : First generation 
 Category : Antibacterial. 
 IUPAC   
 Name : 7 – ( D – 2 - amino – 2 – (4 hydroxy 
  pheny1) amino acetyl 
  13 – Methy 1 – 3 – Cephom – 4 – 
  Carboxylic acid Monohydrate. 
 Colour : White to off white 
 Molecular   
 formula : C16 H17 N3 05 S 
 Molecular   
 Weight : 363.389 gl mol 
 Solubility : 
Slightly soluble in Water and  freely soluble in 
methanol 
 Bioavailability : 80% 
 Protein binding : 28% 
 Half life : 1.5hrs. 
 dose : 125 & 250 mg. 
 
STRUCTURE OF CEFADROXIL  
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A)  CHEMISTRY 
 CEFADROXIL is a first generation oral Cephalosporin. CEFADROXIL is 
water soluble and acid stable. 
 Ambroxol is a mucolytic agent which has an action on reducing the 
viscosity of the mucous in the respiratory tract. Chemically CEFADROXIL is 7-(D-
2-amino-2-(4-hydroxy phenyl) amino acetyl 3-methyl-3-cepham-4-carboxylic acid 
monohydrate. 
B)  STRUCTURE ACTIVITY RELATIONSHIP 
For Oral Cephalosporin 
 For oral cephalosporins a short C3 side chain and phenyl acetylamino side 
chain at C7 appear to be relevant. 
 In the CEFADROXIL structure apart from C3 and C7 substituents another 
attachment in the CEFADROXIL molecule plays an important role. 
Structure Activity 
 Beta-lactam ring fused with Cepham ring Essential for antibacterial 
activity Beta - lactamase stability 
 C3 methyl group 
 Terminal hydroxy group Unique in CEFADROXIL and confers the longer 
plasma and tissue half-life 
C)  SPECTRUM 
 CEFADROXIL, like the other first generation Cephalosporins is active 
against a wide variety of gram +ve and gram -ve organisms. 
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 Among the gram +ve organisms, CEFADROXIL is effective against most 
gram +ve pathogens including most penicillinase-producing staphylococci. 
 Among the gram -ve organisms, only E.coli, Klebsiella pneumoniae and 
Proteus mirabills are commonly susceptible. 
 Against H. influenzae, CEFADROXIL is immediately active. 
 CEFADROXIL is not active against most isolates of Proteus vulgaris, 
Proteus rettgeri, Enterobacter species, Pseudomonas aeruginosa, Citrobacter species, 
Acinetobacter species and Serratia marcescens. 
D)  MIC OF CEFADROXIL AGAINST VARIOUS ORGANISMS 
 Organisms MIC (mcg/ml) 
 Gram-Positive Bacteria 
 Staph. pyogenes (non-penicillinase producer) 2.0 
 Staph. pyogenes (penicillinase producer) 8.0 
 Strep. pyogenes (Group A) 0.63 
 Strep. faecalis (Enterococcus group) 57.0 
 Gram-Negative Bacteria 
 Escherichia coli 16.0 > 125.0 
 Klebsiella 4.0 - 125.0 
 Enterobacter spp. > 125.0 
 Proteus mirabilis 4.0 - 63.0 
 Proteus (other than mirabilis) > 125.0 
 Providencia spp. > 125.0 
 Serratia spp. > 125.0 
 Haemophilus influenzae 8.0 - 63.0 
 Pseudomonas aeruginosa > 125.0 
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E)  MODE OF ACTION 
 CEFADROXIL acts by inhibiting the synthesis of PEPTIDOGLYCAN, a 
major component of the cell wall in multiplying bacteria. 
F)  STRUCTURE OF BACTERIAL CELL 
 The cell wall in bacteria is complex and relatively inelastic. Its main 
function is to confer shape to the organism and protect it from the external 
environment. The cell wall of the gram-positive bacteria differs from and is simpler 
than that of gram-negative bacteria. Peptidoglycan in both Gram-positive and Gram-
negative bacterial cell wall maintains rigidity of the cell and is therefore responsible 
for the essence of the cell. 
 The beta-lactams act by inhibiting peptidoglycan synthesis but only in 
multiplying cells. They do not affect the pre-formed peptidoglycan. 
Cell multiplication involves: 
1. Breaking of peptidoglycan lattice to allow entry of new cell material 
(CELL ELONGATION).  
2. Formation of a cross wall or septum which splits the parent cell (now 
elongated) into identical daughter cells.  
 Both theses processes involve secretion of endogenous lytic enzymes 
known as AUTOLYSINS. As soon as cell multiplication is complete, the autolysin 
secretion stops. If for some reason the autolysins go out of gear and cannot be 
stopped, the cells will undergo self destruction.  
 Beta-lactam compounds bind to Penicillin Binding Proteins and thereby 
inactivate endogenous inhibitors of autolysins. Autolysins then go haywire and 
disrupt the covalent bonds in the bacterial cell wall and cause bacterial lysis.  
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G)  PHARMACOKINETICS 
 A unique feature of Cefadroxyl 
 The choice of an oral Cephalosporin depends on pharmacokinetic factors, 
such as long half-life and duration of action which may influence patient 
compliance. 
 The pharmacokinetic profile of CEFADROXIL differs from those of 
Cephalexin and Cephradine in its more prolonged duration of activity and 
significantly slower rate of excretion. This provides a broadening of the area under 
the plasma concentration-time curve (AUC), and results in higher plasma and urine 
concentrations over an extended period of time. Further the absorption of 
CEFADROXIL is virtually unaffected by food. These characteristics permit the 
administration of CEFADROXIL by a once - or twice-daily dosage regimen. 
 CEFADROXIL is well absorbed from the gastrointestinal tract. Almost 
85% of the drug is absorbed. The peak serum concentrations of CEFADROXIL in 
healthy subjects after 0.5 and 1g doses were 16 and 28 mcg/ml, respectively, 2 hours 
after administration. Predictably, serum levels obtained after administration of 
500mg CEFADROXIL are approximately twice as those obtained with lower dose. 
Unlike Cephalexin, food doesn't interfere with absorption. 
 The area under the curve (of CEFADROXIL) was 82.94 + 19.98 mcg/ml. 
The area under serum concentration versus time curve is larger and bioavailability 
greater for CEFADROXIL. High peak concentration and a large AUC necessary for 
effective antibiotic therapy are achieved with cefadroxil. In a five day multiple dose 
study CEFADROXIL pharmacokinetics were virtually unaltered and no drug 
accumulation was seen as 95% of the dose administered was excreted within 24 
hours. 
 It has been shown that CEFADROXIL is water soluble and has a fair 
degree of lipid solubility. Volume of distribution is 20.65 + 3.9 lit/1.73 m2. The 
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volume of distribution of a drug is an indicator of penetration to tissues. 
CEFADROXIL is widely distributed to body tissues and fluids under normal and 
certain pathological conditions. Concentrations of CEFADROXIL are detectable in 
the tonsils, lungs, liver, gall bladder, bone, muscle, synovial capsule, prostate and 
gynecological tissues and in most body fluids, bile, sputum, amniotic fluid, breast 
milk, skin blisters and aqueous humour. CEFADROXIL is 20 percent serum protein 
bound. As CEFADROXIL is eliminated more slowly, it remains in body tissues for 
longer, after single doses. 
 The concentration of CEFADROXIL in the tonsillar tissue of adults 
undergoing tonsillectomies was approximately three times that of Cephalexin after 1 
gm dose. After 4 hours, the concentration of CEFADROXIL in tissue was found to 
be 10 times the MIC for beta-hemolytic streptococci. 
 In three subjects without infection, concentrations of CEFADROXIL in 
saliva 3-4 hours after drug administration were 3.5 - 3.8 mcg/ml with a mean value 
of 3.6 mcg/ml and represented 40 to 112% of those found in serum. 
 Concentrations of CEFADROXIL in sputum collected from patients with 
exacerbations of chronic bronchitis ranged from 0.1 - 3.8 mcg/ml, with a mean value 
of 1.6 mcg/ml, when measured 2-4 hours after a 1g dose. 
 In 7 patients given a single dose of CEFADROXIL 500mg, peak 
concentrations of about 3.5 mcg/ml were attained in pleural fluid 6 to 8 hours later. 
After a single 500mg dose, CEFADROXIL was detectable in the pleural fluid for 
more than 12 hours. 
 Levels of antibiotic in lung tissue, which represented 54-69% of serum 
values, ranged from 3.8 to 11.5 mcg/ml (mean 8.2 mcg/ml). These levels appeared 
to decrease proportionately with serum levels. Substantial concentrations of 
CEFADROXIL are still detectable in lung tissue at 5 hours following 
administration. Concentrations of CEFADROXIL in the plasma and prostatic tissue 
measured at intervals from 1-5 hours after drug administration exceeded 10 ug/g. 
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CEFADROXIL reaches significant concentrations in the hepatobiliary system. The 
peak concentrations of CEFADROXIL in skin blister fluid was 20mcg/ml after 3 
hours and the peak concentration of Cephalexin was 13.7mcg/ml after 2 hours. 
CEFADROXIL penetrates well into intraocular fluid. CEFADROXIL is not 
metabolized in the body. It is excreted unchanged in the urine by a double process of 
glomerular filtration and tubular secretion. 
 93% of a 0.5g oral dose is excreted in the urine during the first 24 hours, 
most of this occurs during the first 6 hours. When range of 400 - 2400 mg per ml. 
This explains its efficacy against gram negative rods like proteins, Klebsiella & 
E.coli causing urinary tract infection. 
H)  SUMMARY 
 Cefadroxil is almost completely absorbed (85%) after oral administration. 
No drug accumulation is seen on multiple dosing of Cefadroxil. 
 Food does not interfere with absorption of Cefadroxil. 
 High peak serum concentrations are obtained 1½ - 2 hours after oral 
administration. The Area Under Curve (AUC) is greater indicating greater 
bioavailability and effective antibiotic therapy. 
 Slower rate of elimination of CEFADROXIL results in longer duration of 
action. 
 In renal and hepatic impairment, CEFADROXIL, accumulates in patients 
with impaired renal function, but dosage adjustment is not necessary until creatinine 
clearance falls to less than 25 ml/min. No dose adjustments necessary in patient with 
hepatic impairment. 
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I)  ADVERSE REACTIONS 
 Side effects were reported in 6.3% of the patients evaluated. The most 
frequent complaints during CEFADROXIL therapy have been gastrointestinal 
disturbances such as nausea and/or vomiting and less frequently diarrhoea. 
 Hypersensitivity reactions in the form of allergy such as rash, urticaria and 
dermatitis have been encountered less frequently with CEFADROXIL. 
J)  CONTRAINDICATIONS 
 CEFADROXIL is contraindicated in patients with known allergy to the 
Cephalosporin group of antibiotics. 
K)  PRECAUTIONS 
 CEFADROXIL should be used with caution in the presence of markedly 
impaired renal function (creatinine clearance rate of less than 50 ml/min/1.73 m2). 
 In patients with known or suspected renal impairment, careful clinical 
observation and appropriate laboratory studies should be made prior to and during 
therapy. 
L) USE IN PREGNANCY 
 There are, however, no adequate and well controlled studies in pregnant 
women. Because animal reproduction studies are not always predictive of human 
response, this drug should be used during pregnancy only if clearly needed. 
M)  DOSAGE AND ADMINISTRATION 
 CEFADROXIL is acid stable and may be administered orally with or 
without meals. Administration with food may be helpful in diminishing potential 
gastrointestinal complaints occasionally associated with oral cephalosporin therapy. 
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 The property of CEFADROXIL being unaffected by the presence of food 
offers patient compliance, particularly to paediatric patients since their eating habits 
are so difficult to regulate. 
a) ADULT DOSAGE 
 Respiratory Tract Infections/ Pharyngitis and Tonsilllitis 
 For mild infections - Treatment of Group A hemolytic streptococcal 
pharyngitis and tonsillitis - 1gm per day in divided doses (B.I.D.) for 10 days. 
Lower Respiratory 
 1 gm per day in divided doses 
Tract Infections 
 For moderate to severe infections, the recommended dose is 1-2 gms daily 
in two divided doses. 
Skin and Soft Tissue Infections 
 1 gm per day in single or divided doses (b.i.d). 
b)  PAEDIATRIC DOSAGE 
 The recommended daily dosage for children is 30mg/kg/day in divided 
doses for every 12 hours. In the treatment of beta-hemolytic streptococcal infections, 
a therapeutic dosage of CEFADROXIL should be administered for at least 10 days. 
c)  Dosage In Renal Impairment 
 In patients with renal impairment, the dosage of CEFADROXIL should be 
adjusted according to creatinine clearance rates. 
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 In adults the initial dose is 1,000 mg of CEFADROXIL and maintenance 
dose is 500mg, the frequency depending on creatinine clearance. 
Creatinine Clearance Dosage Interval 0-10 ml/min 36 hrs 
 10-25 ml/min 24 hrs 
 25-50 ml/min 12 hrs 
 Patients with creatinine clearance over 50ml/min may be treated as if they 
were patients having normal renal function. 
N)  CLINICAL INDICATIONS 
 Adults 
1. Infections of the Upper Respiratory Tract Acute and Chronic 
Sinusitis/Pharyngitis  
2. E.N.T. Infections  
 Otitis Media 
3. Infections of the Lower Respiratory Tract Bacterial Pneumonia  
 Acute Bronchitis Chronic Bronchitis  
 Chronic Obstructive Pulmonary Disease (COPD) Bronchiectasis  
4. Urinary Tract Infections  
5. Skin and Soft Tissue Infections  
 Impetigo 
 Folliculitis 
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 Furuncles and Carbuncles 
 Paronychia 
 Erysipelas 
 Ecthyma 
 Cellulitis 
6. Osteomyelitis  
7. Ophthalmic infections  
8. Gynaecological conditions  
 Infants and Children 
1. Group A Streptococcal Pharyngitis  
2. Sinusitis  
3. Otitis Media  
4. Bronchitis  
5. Pneumonia or Bronchopneumonia  
6. Urinary Tract Infections  
7. Acute Gastroenteritis  
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EXCIPIENT USED FOR STUDY 
SODIUM BICARBONATE 
 Synonyms: Backing soda, E500, Monosodium carbonate, Sodium acid 
carbonate, Sodium hydrogen carbonate. 
Nonproprietary Name 
 B.P.:  Sodium Bicarbonate. 
 USP : Sodium Bicarbonate 
Chemical name 
 Carbonic acid monosodium salt. 
Molecular weight: 84.01 
Structural formula: NaHCO3 
Description 
 Sodium Bicarbonate occurs as odourless, White crystalline powder with 
saline, slightly alkaline taste. Crystal structure is monolithic prisms. Commercially 
different particle size from fine powder to free flowing granules available. 
Solubility 
 Practically insoluble in Ethanol (95%) and Ether at 200C. In water 1 in 11 
at 20 0C and 1 in 4 at 100 0C. 
Functional Category:  Alkalizing agent, Therapeutic agent. 
Application: Pharmaceutical application shows in table. 
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Table No. 8 : Application 
Use Concentration 
Buffer in tablets 10-40% 
Effervescent tablets 25-50% 
Isotonic injection/Infusion 1.39% 
 
Typical Property 
 Density: 2.159g/cm3  
 Melting point: 270 0C  
 Acidity/Alkalinity: pH 8.3 for a freshly prepared 0.1M aqueous solution at 
250C. 
Stability and Storage Conditions: Stable in dry air but slowly decompose in moist 
air and therefore be stored in well closed container in cool, dry place. 
Safety: Generally regarded as non toxic and non irritant. 
MAGNESIUM STEARATE:59 
Synonyms: Metallic stearic, Magnesium salt. 
Nonproprietary Name: NF: Magnesium stearate. 
    BP/EP: Magnesium stearate. 
Functional category: Tablet and capsule lubricant. 
Chemical names: Octadecanoic acid, Magnesium salt, Magnesium stearate. 
CAS Registry number:  557-04-0 
Empirical formula: C36H70MgO4 
Molecular weight: 591.3 
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Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water, slightly 
soluble in benzene and warm ethanol (95%). 
 
Structural Formula: CH3(CH2)16COO   
 
 Mg 
 
 
CH3(CH2)16COO 
 
 Magnesium  Stearate 
 
 
Description: It is a fine, white, precipitated or milled, impalpable powder of low 
bulk density. 
 Density (He): 1.03-1.08 g/cm3  
 Bulk volume: 3.0-8.4 ml/g  
 Tapped volume: 2.5-6.2 ml/g.  
Applications: Tablet and capsule lubricant, glidant and antiadherent in the 
concentration range of 0.25 to 2.0%. 
Stability and Storage Conditions: Stable, non-self polymerizable. Store in a cool, 
dry place in a well closed container. 
Incompatibilities: Incompatible with strong acids, alkalies, iron salts and with 
strong oxidizing materials. 
Safety: Described as inert or nuisance dust. However, oral consumption of large 
quantities may result in some laxative effect or mucosal irritation. 
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HYDROXYPROPYL METHYLCELLULOSE (K15M):59 
Composition and chemical structure: 
 
 
 
 
 
Synonyms: Cellulose, hydroxypropyl methyl ether, methocel, metolose, 
pharmacoat, HPMC, methylcellulose propylene glycol ether. 
Nonproprietary names: BP: Hypromellose 
  PhEur: Methylhydroxypropylcellulosum  
  USP: Hydroxypropyl methylcellulose 
Chemical names: Cellulose, 2-Hydroxypropyl methyl ether. 
Molecular weight: 10,000 - 15, 00,000. 
Category: Coating agent; film former; stabilizing agent; suspending agent; tablet 
binder; viscosity-increasing agent. 
Description: It is an odourless and tasteless, white or creamy-white coloured fibrous 
or granular powder. 
Solubility: Soluble in cold water, insoluble in chloroform, ethanol, and ether, but 
soluble in mixtures of ethanol and dichloromethane and mixtures of methanol and 
dichloromethane. 
Viscosity: The viscosity of the polymer ranges from 75-140% of the declared value. 
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Stability and storage condition: It is stable material although it is hygroscopic after 
drying. Increase in temperature reduces the viscosity of solutions. It is under goes a 
reversible solution to get transformation upon heating and cooling respectively. The 
powder should be stored in a well-closed container in a cool and dry place. 
Safety: It is generally regarded as a non-toxic and non-irritant material although 
excessive consumption may have a laxative effect. 
Application: 
 Chemical ingredient HPMC made by Head Co.,Ltd. are widely used in 
food, cosmetic and other daily use chemical lines. Typical usage as following: 
1.  Medical durg. 
 The product is a medical accessory material of may uses. It can be used for 
densifiers, dispersing agent, emulsifying agent, lubricator and former etc. It's used as 
an adhesive and coating film in tablets, increasing markedly rate of dissolution and 
release, and strengthen water proof for tablets and also be used as mixed dispersing 
agent, eye drop agent, controlled released matrix tablets. It is combined with other 
synthetic polymers and gel-type drug products to prevent ethanol separated from 
transparent gel drug while improve water keep ability. 
2.  Foodstuff 
 HPMC can be directly used to food as effective emulsification agent, 
adhesive, thickening agent as well as can be used as packing materials. 
3.  Cosmetic. 
 According to properties of HPMC, it can be used as thickening agent, 
emulsification agent, suspending agent, stabilizing agent, water retention agent, 
rheological behavior agent. Thus be used in all kinds of cosmetic products. 
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Packing, transport and storage 
 20kg or 25 kg package in polyethylene bag or barrel with inner liners. 
Keep dry where good ventilated. Do not wet, and keep from sunshine when 
transport. 
SODIUM CARBOXYMETHYLCELLULOSE:59 
 
 
 
Where  R = H, CH2COONa or CH2COOH 
Synonyms: Akucell, blanose, cekol, cellulose gum, CMC sodium, courlose, E466, 
nymcel, SCMC, sodium cellulose glycolate, sodium CMC, tylose CB. 
Nonproprietary names: USP : Carboxymethylcellulose sodium 
  PhEur : Carboxymethylcellulosum natricum 
  BP : Carmellose sodium 
Chemical names: Cellulose, carboxymethyl ether, sodium salt. 
Molecular weight: 90,000 – 7, 00,000 
Category: Coating agent, tablet and capsule disintegrant, tablet binder, stabilizing 
agent, suspending agent, viscosity-increasing agent. 
Description: Carboxymethylcellulose sodium occurs as a white to almost white 
coloured, odourless, granular powder. 
Solubility: Practically insoluble in acetone, ethanol, ether and toluene. Easily 
dispersed in water at all temperature forming clear colloidal solution. 
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Viscosity: Various grades of carboxymethylcellulose sodium are commercially 
available which have differing aqueous viscosities; aqueous 1% w/v solutions with 
viscosities of 5 – 4000 mPa s may be obtained. An increase in concentration results 
in an increased in aqueous viscosity. 
Stability and storage condition: It is a stable, though hygroscopic material. Under 
high humidity conditions it can absorb a large quantity of water. It may be sterilized 
in dry state by maintaining it at a temperature of 1600 C for 1 hr. However, this 
process results in a significant decrease in viscosity. The bulk material should be 
stored in a well-closed container in a cool and dry place. 
Safety: It is regarded as a non-toxic and non-irritant material. 
CITRIC ACID 
 Citric acid is a weak organic acid found in citrus fruits. It is a good, natural 
preservative and is also used to add an acidic (sour) taste to foods and soft drinks. In 
biochemistry, it is important as an intermediate in the citric acid cycle and therefore 
occurs in the metabolism of almost all living things. It also serves as an 
environmentally benign cleaning agent and acts as an antioxidant. 
 Citric acid exists in a variety of fruits and vegetables, but it is most 
concentrated in lemons and limes, where it can comprise as much as 8% of the dry 
weight of the fruit. 
 
 
 
 Citric acid's chemical formula is C6H8O7 (structure shown at right). Its 
structure is reflected in its IUPAC name 2-hydroxypropane-1,2,3-tricarboxylic 
acid. 
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Description: white or colourless, odourless, crystalline solid 
Solubility: Very  soluble in water, freely soluble in ehanol and slightly soluble in 
ether 
Properties: The physical properties of citric acid are summarized in the table at 
right. The acidity of citric acid results from the three carboxyl groups COOH which 
can lose a proton in solution. If this happens, the resulting ion is the citrate ion. 
Citrates make excellent buffers for controlling the pH of acidic solutions. 
 Citrate ions form salts called citrates with many metal ions. An important 
one is calcium citrate or "sour salt", which is commonly used in the preservation and 
flavoring of food. Additionally, citrates can chelate metal ions, which gives them use 
as preservatives and water softeners. 
 At room temperature, citric acid is a white crystalline powder. It can exist 
either in an anhydrous (water-free) form, or as a monohydrate that contains one 
water molecule for every molecule of citric acid. The anhydrous form crystallizes 
from hot water, while the monohydrate forms when citric acid is crystallized from 
cold water. The monohydrate can be converted to the anhydrous form by heating it 
above 74 °C. 
 Chemically, citric acid shares the properties of other carboxylic acids. 
When heated above 175°C, it decomposes through the loss of carbon dioxide and 
water. 
Uses 
 Most citric acid is used as a flavouring and preservative in food and 
beverages, especially soft drinks; it is denoted by E number E330. Citrate salts of 
various metals are used to deliver those minerals in a biologically available form in 
many dietary supplements. The buffering properties of citrates are used to control 
pH in household cleaners and pharmaceuticals. 
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 Citric acid's ability to chelate metals makes it useful in soaps and laundry 
detergents. By chelating the metals in hard water, it lets these cleaners produce foam 
and work better without need for water softening. Similarly, citric acid is used to 
regenerate the ion exchange materials used in water softeners by stripping off the 
accumulated metal ions as citrate complexes. 
 It is used in the biotechnology and pharmaceutical industry to passivate 
high purity process piping in lieu of using nitric acid, since nitric acid is a hazardous 
disposal issue once it is used for this purpose, while citric acid is not. 
 Citric acid is one of the chemicals required for the synthesis of HMTD; a 
highly heat, friction, and shock sensitive explosive similar to Acetone peroxide (also 
know as "Mother of Satan"). Due to this the purchase of large quantities citric acid 
may be seen by some governments as a indicator of potential terrorist activity. 
 Citric acid can also be added to ice cream to keep fat globules separate. 
 Citric acid can be added to recipes in place of fresh lemon juice. 
Safety 
 Citric acid is recognized as safe for use in food by all major national and 
international food regulatory agencies. It is naturally present in almost all forms of 
life, and excess citric acid is readily metabolized and eliminated from the body. 
 Contact with dry citric acid or with concentrated solutions can result in 
skin and eye irritation, so protective clothing should be worn when handling these 
materials. 
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Guar Gum: Structure Diagram 
 
 
 
 
 
 Guar Gum has excellent cold water solubility because of the high 
galactose: mannose ratio. The special properties of GUAR GUM known in india 
make it most suitable for various industrial applications. 
Guar Gum Chemical Properties 
 Guar gum is an economical thickener and stabilizer. It hydrates fairly rapidly 
in cold water to give highly viscous pseudo plastic solutions of generally 
greater low-shear viscosity when compared with other hydrocolloids and 
much greater than that of locust bean gum.  
 High concentrations (~ 1%) are very thixotropic but lower concentrations (~ 
0.3%) are far less so.  
 Guar gum is more soluble than locust bean gum and a better emulsifier as it 
has more galactose branch points.  
 Unlike locust bean gum, it does not form gels but does show good stability to 
freeze-thaw cycles.  
 Guar gum shows high low-shear viscosity but is strongly shear-thinning. 
Being non-ionic, it is not affected by ionic strength or pH but will degrade at 
pH extremes at temperature for e.g. pH 3 at 50°C. With case in, it becomes 
slightly thixotropic forming a biphasic system containing casein micelles.  
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Guar Gum Properties 
The main properties of Guar gum are 
 It is soluble in hot & cold water but insoluble in most organic solvents.  
 It has strong hydrogen bonding properties.  
 It has excellent thickening, Emulsion, Stabilizing and film forming 
properties.  
 At very low concentration, Guar gum has excellent settling (Flocculation) 
properties and it acts as a filter aid.  
 It is non ionic and maintains a constant high viscosity over a broad range of 
ph.  
 It is compatible with a variety of inorganic and organic substances including 
certain dyes and various constituents of food.  
 The viscosity of Guar gum solution increase gradually with increasing 
concentration of Guar gum in water.  
 The viscosity of Guar gum is influenced by temperature, ph, presence of salts 
and other solids.  
 It has excellent ability to control rheology by economic water phase 
management.  
 It forms highly viscous colloidal dispersions when hydrated in cold water. 
The time required for complete hydration in water and to achieve maximum 
viscosities depends on various factors i.e. the ph; temperature; grade of 
powder used; Equipment etc.  
Guar Gum Viscosity: The most important characteristic of guar is its ability to be 
dispersed in water and hydrate or swell rapidly and almost completely in clod water 
to form viscous colloidal dispersions or sols. 
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 The viscosity attained is dependent on time, temperature, concentration, 
pH, rate of agitation and practical size of the powdered gum used. The lower the 
temperature lower the rate at which viscosity increases and the lower the final 
viscosity. 
 Above 80º the final viscosity is slightly reduced. The finer guar powders 
swells more rapidly than coarse powdered gum. 
Uses 
 Guar Gum is mainly used as a  
 Natural thickener  
 Emulsifier  
 Stabiliser  
 Bonding agent  
 Hydrocolloid  
 Gelling agent  
 Soil Stabiliser  
 Natural fiber  
 Flocculants  
 Fracturing agent  
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Guar Gum for Pharmaceutical Industries: 
 Guar gum powder is used in pharmaceutical industries as Gelling/ 
Viscosifying/Thickening, Suspension, Stabilization, Emulsification, 
Preservation, Water Retention/Water Phase control, Binding, 
Clouding/Bodying, Process aid, Pour control for following applications.  
 In tablet manufacturing it is used as a binder and disintegrating agent and in 
micro-encapsulation of drugs.  
 Suspensions  
 Anti-acid formulations  
 Tablet binding and disintegration agent  
 Controlled drug delivery systems  
 Slimming aids  
 Nutritional food  
 Guar gum has a polymeric structure, containing several hydroxyl groups. 
The various derivatives or industrial grades of Guar gum are manufactured 
by reaction of these hydroxyl groups with chemicals that aid in  
 Dispersion  
 Control Viscosity  
STARCH 
Starch or amylum is a polysaccharide carbohydrate consisting of a large number of 
glucose units joined together by glycosidic bonds. Starch is produced by all green 
plants as an energy store. It is the most important carbohydrate in the human diet 
and is contained in such staple foods as potatoes, wheat, maize (corn), rice, and 
cassava. 
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STRUCTURE OF STARCH
 Starch or amylum 
number of glucose units joined together by
all green plants as an energy store. It is the most important carbohydrate in the 
human diet and is contained in such staple foods as potatoes, wheat, maize (corn), 
rice, and cassava. 
 
 
 
 
 
 
STRUCTURE 
 Starch molecu
granules. Each plant species has a unique starch granular size: rice starch is 
relatively small (about 2 
m). Although in absolute mass only abo
plants consist of amylose, there are about 150 times more amylose molecules than 
amylopectin molecules. Amylose is a much smaller molecule than amylopectin
DESCRIPTION 
 Pure starch is a white, tasteless and odorle
cold water or alcohol. It consists of two types of molecules: the linear and helical 
amylose and the branched amylopectin. Depending on the plant, starch generally 
contains 20 to 25% amylose and 75 to 80% amylopectin.
store of animals, is a more branched version of amylopectin.
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 Starch can be used as a thickening, stiffening or gluing agent when 
dissolved in warm water, giving wheatpaste. 
SOLUBILITY 
 Starch becomes soluble in water when heated. The granules swell and 
burst, the semi-crystalline structure is lost and the smaller amylose molecules start 
leaching out of the granule, forming a network that holds water and increasing the 
mixture's viscosity. This process is called starch gelatinization. During cooking the 
starch becomes a paste and increases further in viscosity. During cooling or 
prolonged storage of the paste, the semi-crystalline structure partially recovers and 
the starch paste thickens, expelling water. This is mainly caused by the 
retrogradation of the amylose. This process is responsible for the hardening of bread 
or staling, and for the water layer on top of a starch gel (syneresis). 
 Some cultivated plant varieties have pure amylopectin starch without 
amylose, known as waxy starches. The most used is waxy maize, others are 
glutinous rice, waxy potato starch. Waxy starches have less retrogradation, resulting 
in a more stable paste. High amylose starch, amylomaize, is cultivated for the use of 
its gel strength. 
 Glucose is soluble in water, hydrophilic, binds much water and then takes 
up much space; glucose in the form of starch, on the other hand, is not soluble and 
can be stored much more compactly. 
 Since starch is a reserve sugar for the plant, glucose molecules are bound 
in starch by the easily hydrolyzed alpha bonds. The same type of bond can also be 
seen in the animal reserve polysaccharide glycogen. This is in contrast to many 
structural polysaccharides such as chitin, cellulose and peptidoglycan, which are 
bound by beta-ties and are much more resistant to hydrolysis. 
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BIOSYNTHESIS 
 Plants produce starch by first converting glucose 1-phosphate to ADP-
glucose using the enzyme glucose-1-phosphate adenylyltransferase. This step 
requires energy in the form of ATP. The enzyme starch synthase then adds the ADP-
glucose via a 1,4-alpha glycosidic bond to a growing chain of glucose residues, 
liberating ADP and creating amylose. Starch branching enzyme introduces 1,6-alpha 
glycosidic bonds between these chains, creating the branched amylopectin. The 
starch debranching enzyme isoamylase removes some of these branches. Several 
isoforms of these enzymes exist, leading to a highly complex synthesis process.[3] 
While amylose was traditionally thought to be completely unbranched, it is now 
known that some of its molecules contain a few branch points.[4] 
 Glycogen and amylopectin have the same structure, but the former has 
about one branch point per ten 1,4-alpha bonds, compared to about one branch point 
per thirty 1,4-alpha bonds in amylopectin.[5] Another difference is that glycogen is 
synthesised from UDP-glucose while starch is synthesised from ADP-glucose. 
HYDROLYSIS 
 The enzymes that break down or hydrolyze starch into the constituent 
sugars are known as amylases. 
 Alpha-amylases are found in plants and in animals. Human saliva is rich in 
amylase, and the pancreas also secretes the enzyme. Individuals from populations 
with a high-starch diet tend to have more amylase genes than those with low-starch 
diets; chimpanzees have very few amylase genes. It is possible that turning to a 
high-starch diet was a significant event in human evolution.[6] 
 Beta-amylase cuts starch into maltose units. This process is important in 
the digestion of starch and is also used in brewing, where the amylase from the skin 
of the seed grains is responsible for converting starch to maltose (Malting, 
Mashing). 
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INDUSTRIAL APPLICATION 
 Papermaking  
 Corrugated board  
 Clothing starch or laundry starch  
 Textile chemicals  
 Hydrogen production  
 Printing industry  
 Oil exploration  
 Body powder  
USES 
 As an additive for food processing, food starches are typically used as 
thickeners and stabilizers in foods such as puddings, custards, soups, sauces, 
gravies, pie fillings, and salad dressings, and to make noodles and pastas.  
 But by far the most common starch based food ingredient are starch sugars 
(see below) used as sweetener in many drinks and foods.  
 Use as a mold. Gummed sweets such as jelly beans and wine gums are not 
manufactured using a mold in the conventional sense. A tray is filled with 
native starch and leveled. A positive mold is then pressed into the starch 
leaving an impression of 1000 or so jelly beans. The mix is then poured into 
the impressions and then put into a stove to set. This method greatly reduces 
the number of molds that must be manufactured.  
 Starch is used as an excipient, a binder in medications to aid the formation of 
tablets.  
 Resistant starch is starch that escapes digestion in the small intestine of 
healthy individuals.  
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6. MATERIALS AND METHODS 
MATERIALS USED  
Table No. 9 List of chemicals used with their grade and supplier 
SI.No. Material Supplier 
1. Cefadroxil Eleghant Pharmaceutical, Hubli. 
2. Hydroxyl propyl methyl 
Cellulos   K100M 
Miltons laboratory, Pondy. 
3 Sodium carboxy methyl cellulose Micro labs, Hosur. 
4. Citric acid Micro labs, Hosur. 
5. Sodium bicarbonate Micro labs, Hosur. 
6. Magnesium Stearate Micro labs, Hosur. 
7. Gum Guar Micro labs, Hosur. 
8. Starch Micro labs, Hosur. 
 
Equipments used 
Table No.10   Details of Equipments Used 
SI. No. Instrument Manufacture 
1. Digital balance Sartorious 
2. Tablet hardness tester Monsanto 
3. Friability Tester Roche Friabilitor 
4. Vernier Tester Mitutoyo 
5. UV spectro photometer (double beam) 1700 Shimadzu 
6. Rotary tablet Punching Machine Rimek Minipress-1 
7. pH meter Systronics, Naroda, 
Ahmedabad 
8. FTIR Spectrophotometer Shimadzu 
9. Environmental Test Chamber Heco. 
10. Dissolution Apparatus Electro lab ( Tablet 
Dissolution Tester 
USP-24 ) 
11. Sieve Jayant Scientific Industry 
 
6.3. LIST OF REAGENT  
 Potasium hydrogen phthalate  
 Sodium hydroxide  
 0.1N hydrochloric acid  
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PREFORMULATION STUDIES 
 Pre formulation testing is the first step in the rational development of 
dosage forms of a drug substance. It can be defined as an investigation of physical 
and chemical properties of a drug substance alone and when combined with 
excipients. The overall objective of pre-formulation testing is to generate 
information useful to the formulator in developing stable and bio available dosage 
forms that can be man produced. 
The following preformulation studies are carried out: 
 Physical appearance 
 Solubility 
 Melting point 
 Finding the absorption maxima 
 Infra red spectroscopy studies (compatibility studies) 
 Standard curve of cefadroxil in distilled water 
 Standard curve of cefadroxil in 0.1 N HCL 
Organoleptic properties 
Color 
 A small quantity of cefadroxil powder was taken in butter paper and 
viewed in well illuminated place. 
Taste and Odour 
 Very less quantity of cefadroxil was used to get taste with the help of 
tongue as well as smelled to get the odour. 
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Melting point:32,33 
 It is one of the parameters to judge the purity of crude drugs. In case of 
pure chemicals or phytochemicals, melting points are very sharp and constant. Since 
the crude drugs contain the mixed chemicals, they are described with certain range 
of melting point. 
Procedure 
 A small quantity of powder was placed into a fussion tube. That tube is 
placed in the melting point determining apparatus containing castor oil. The 
temperature of the castor oil was gradual increased automatically and read the 
temperature at which powder started to melt and the temperature when all the 
powder get melted. 
Solubility 
 A semi quantitative determination of the solubility was made by adding 
solvent in small incremental amount to a test tube containing fixed quantity of solute 
or vice versa. After each addition, the system vigorously shaken and examined 
visually for any undissolved solute particles. The solubility was expressed in turms 
of ratio of solute and solvent. 
Finding the absorption maxima (λ max ) 
The absorption maxima was found for drug identification. 
 Ultraviolet Visible spectrophotometry has been used to obtain specific 
information on the chromophoric part of the molecules. Organic molecules in 
solutions when exposed to light in the visible/Ultraviolet region of the spectrum 
absorb light of particular wavelength depending on the type of electronic transition 
associated with the absorption. 
 
 The drug solutions (5, 10, 15, 20, 25µg/ml) in distilled water was taken in 
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a standard cuvette and scanned in the range of 200-400 nm in UV 
spectrophotometer. It exhibits maxima at 263 nm. Therefore further all 
measurements were taken at 263nm Results given in Fig 23, 24. 
Identification By IR 52, 66 
 The IR spectrums of the sample of the metoprolol succinate working 
reference standard in the range of 2000 cm-1 to 500 cm-1 were taken by preparing 
dispersion in dry potassium bromide under the same operational conditions. 
Superimposed these spectra. The transmission minima {absorption maxima) in the 
spectrum obtained with the sample corresponded in position and relative size to 
those in the spectrum obtained with the Domperidone working/reference standard. 
Results given in Table No. 16-20. 
Preparation of Standard Curve of Cefadroxil with Distilled Water 
Preparation of stock solutions 
 Weighed accurately 100 mg of cefadroxil and dissolved in a few ml of 
distilled water in a 100ml volumetric flask. Then the volume was made upto 100ml 
with the distilled water, which gives 1000 g/ml concentration. 
Preparation of Various concentrations: 
I) 5  g/ml solution:  
 0.5ml of stock solution added in 100 ml volumetric flask and made up with 
distilled water.  
II) 10  g/ml solution:  
 1 ml of stock solution added in 100 ml volumetric flask and made up with 
distilled water.  
III) 15  g/ml solution 
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 1.5 ml of stock solution added in 100 ml volumetric flask and made up 
with distilled water.  
IV)  20  g/ml solution 
 2 ml of stock solution added in 100 ml volumetric flask and made "up with 
distilled water. 
V) 25  g/ml solution: 
 2.5 ml of stock solution added in 100 ml volumetric flask and made up 
with distilled water.  
 The above concentration solution were checked absorbance at 263 nm by 
using UV spectrophotometer and distilled water was used as blank solution. The 
result given in Table No.21 
Preparation of Standard Curve of Cefadroxil with 0.1 n HCl 
Preparation of stock solutions 
 Weighed accurately 100 mg of cefadroxil and dissolved in a few ml of 0.1 
N HCl in a 100ml volumetric flask. Then the volume was made upto 100ml with the 
0.1 N HCl, which gives 1000 g/ml concentration. 
Preparation of Various concentrations 
I) 5  g/ml solution 
 0.5 ml of stock solution added in 100 ml volumetric flask and made up 
with 0.1 N HCl.  
 
II) 10  g/ml solution 
 1 ml of stock solution added in 100 ml volumetric flask and made up with 
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0.1 N HCl.  
III) 15  g/ml solution 
 1.5 ml of stock solution added in 100 ml volumetric flask and made up 
with 0.1 N HCl.  
IV)  20  g/ml solution 
 2 ml of stock solution added in 100 ml volumetric flask and made "up with 
0.1 N HCl. 
V) 25  g/ml solution 
 2.5 ml of stock solution added in 100 ml volumetric flask and made up 
with 0.1 N HCl.  
 The above concentration solution were checked absorbance at 263 nm by 
using UV spectrophotometer and distilled water was used as blank solution. The 
result given in Table No 22 
FORMULATON OF FLOATING TABLETS 
Method of Preparation of Floating Tablets  
 Matrix type floating tablets were prepared by wet granulation method. The 
floating tablets were prepared by using various polymer like HPMC K100M 
(different concentrations) & SCMC by effervescent method. The two different 
strength(125& 250) was prepared for comparision. 
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PROCEDURE 
Sifting 
 Cefadroxil was sifted from mesh No. 60# then Hydroxy Propyl Methyl 
Cellulose – K 15 M (cps), sodium carboxy methyl cellulose, sodium bicarbonate , 
citric aid and guar gum Sifted through mesh No. 30#. Sodium bicarbonate 
Mixing 
 All sifted ingredient is dry mixed thoroughly for not less than 5 min, until 
to get uniform mixed powder. 
Preparation of Granulating Fluid  
 Starch paste-10%  
Granulation  
 Granulating fluid was added on mixed material to get dough mass. 
Milling and Drying 
 Dough mass was milled through sieve No.10 and dried by hot air oven at 
60o C for 30 min to get dry granules. These dried granules were against passed 
through sieve No. 22# The portion retained on sieve was collected. 
Lubrication / Blending 
 Lubricating material magnesium stearate previously were passed through 
sieve No.30 # and mixed thoroughly with granules for not less than 5 min. to get 
uniform granules. 
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Compression 
 The lubricated granules were compressed into tablet using minipress 10 
station tablet punching machine.                      
Table-10 Formulation Table 
CEFADROXIL STRENGTH 125 MG 
SI. 
No Ingredients F1 F2 F3 F4 F5 
1. Cefadroxil 125 125 125 125 125 
2. HPMC K100M 0 50 100 150 200 
3. SCMC 50 50 50 50 50 
4. Sod bicarbonate 140 140 140 140 140 
5. Citric acid 70 70 70 70 70 
6. Gum Guar 10 10 10 10 10 
7. Starch Q.S Q.S Q.S Q.S Q.S 
8. Magnesium Sterate 5 5 5 5 5 
 TOTAL 400 450 500 550 600 
 
Table -11 Formulation Table 
CEFADROXIL STRENGTH 250 MG 
SI. 
No Ingredients F6 F7 F8 F9 F10 
1. Cefadroxil 250 250 250 250 250 
2. HPMC K100M 0 50 100 150 200 
3. SCMC 50 50 50 50 50 
4. Sod bicarbonate 200 200 200 200 200 
5. Citric acid 85 85 85 85 85 
6. Gum Guar 10 10 10 10 10 
7. Starch Q.S Q.S Q.S Q.S Q.S 
8. Magnesium Sterate 5 5 5 5 5 
 TOTAL 600 650 700 750 800 
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OPTIMIZATION  
Evaluation of granules 
Flow properties 
 The flow properties of powders are critical for an efficient tabletting 
operation. A good flow of powder or granulation to be compressed is necessary to 
assure efficient missing and acceptable weight uniformity for the compressed 
tablets. If a drug is identified at the pre formulation stage to be "poorly flowable", 
the problem can be solved by selecting appropriate excipients. In some cases, drug 
powders may have to be pre-compressed or granulated to improve their flow 
properties. During pre formulation evaluation of drug substance, therefore, its 
flowability characteristic should be studied, especially when the anticipated dose of 
the drug is large. 
Angle of repose 
 It is defined as the maximum angle formed beween the pile of powder 
heap and the radius of powder. The results are discussed in table :23,24 
Procedure 
 A funnel was kept vertically in a stand at a specified height above a paper 
placed on a horizontal surface. The funnel bottom is closed and 10 gm of sample 
powder is filled in funnel. Then funnel was opened to release the powder on the 
paper to form a smooth conical heap, is found by measuring in different direction. 
The height of the heap was measured by using scale. The value of angle of repose 
are calculated by using the following formula. 
 tan θ = h/r 
 θ = tan -1 h/r 
Where,  h; height of the heap 
 r: radius of the heap 
Table -11 Angle of Repose 
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S.NO ANGLE OF REPOSE FLOW PROPERTY 
1 < 25 Excellent 
2 25-30 Good 
3 30-40 Passable 
4 >40 Very poor 
 
Bulk density 
 Bulk density is defined as the mass of powder divided by the bulk volume. 
Bulk density largely depends on particle shape, as the particles become more 
spherical in shape, bulk density is increase. In addition as granules size increase, 
bulk density decrease. 
 Bulk density was determined by measuring the volume of a known mass of 
powder sample that has been passed through a screen into a graduated cylinder 
(method 1) or through a volumetric measuring apparatus into a cup (method 11). 
Procedure: 
 A known quantity of powder was poured into the measuring cylinder 
carefully level the powder without compacting, if necessary and read the unsettled 
apparent volume, Vo, to the nearest graduated unit. Calculate the bulk density, in gm 
per ml, Refer table 23,24 
 
o
mBulk density
v
=  
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Tapped density 
 Tapped density is achieved by mechanically tapping a measuring cylinder 
containing a powder sample. After observing the initial volume, the cylinder is 
mechanically tapped, and volume readings are take until little further volume 
changes is observed. The mechanical tapping is achieved by rising the cylinder and 
allowing it to drop under its own weight a specific distance (by either two method). 
Device that rotate the cylinder during tapping may be preferred to minimize any 
possible separation of the mass during tapping down. 
Cylinder dropping distance: 14± 2 mm at a normal rate of 300 drops / minute. 
 Unless otherwise specified, tab the cylinder 500 times initially and 
measure the tapped volume, Va, to the nearest graduated unit. Repeat the tapping an 
additional 750 times and measured the tapped volume, Vb, to the nearest graduated 
unit. If the difference between the two volume is less than 2%, Vb is the final tapped 
volume, Vf. Repeat in increments of 1250 taps, as needed, unit the difference 
between succeeding measurements is less than 2%. Calculate the tapped density, in 
gm per ml, by the formula: 
 
mTapped density
Vf=  
 Generally replicate determinations are desirable for the determination of 
this property. 
Note; method II: Same as method 1 except that a suitable mechanical tapped density 
tester that provides a fixed drop of 3 mm (±10 %) at a nominal rate of 250 drops per 
minute was used. Results given in Table No. 23, 24 
Measurement of Powder Compressibility 
 The compressibility Index and Hausner Ratio are measures of the 
propensity of a powder to be compressed. As such, they are measures of the relative 
importance of inter particulate interactions. In a free flowing power, such 
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interactions are generally less and tapped densities will be closer in value. For 
poorer flowing materials, there are frequently greater inter particle interactions, and 
a greater difference between bulk and tapped densities will be observed. These 
differences are reflected in the compressibility Index and the Hausner Ratio 
Calculated by the formula. Result given in Table No. 23,24 
0( )100
o
V VfCompressibility Index
V
−
=  
Table No.12 Compressibity index 
S.NO COMPRESSIBILITY INDEX FLOW PROPERTY 
1 5-15 Excellent 
2 12-16 Good 
3 18-23 Fair to passable 
4 23-25 Poor 
5 33-38 Very poor 
6 >40 Extremely poor 
 
8.2.1.5 Hausners ratio 
 It is the ratio of tapped density to the bulk density.  
 Hausners ratio= tapped density / bulk density. 
Table-13 Hausners ratio 
S.NO HASNER RATIO FLOW PROPERTY 
1 < 1.25 Good 
2 1.25-1.5 Moderate 
3 > 1.5 Poor 
              REFER TABLE NO.23, 24
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RESULTS 
 
Weight Variation Test 
 Twenty tablets were randomly selected and weighed to determine the average 
weight and were compared with individual tablet weight. The percentage weight 
variation was -calculated. As per Indian Pharmacopoeial Specification, tablets with an 
average weight between 80 – 250 mg, the percentage deviation should not more than ± 7. 
5 % and tablets with an average weight more than 250 mg should not be more than ±10 
%. Results given in Table No. 25,26 
Weight variation (TABLE-14) 
SI.NO AVERAGE WEIGHT % DEVIATION 
1 80 mg or less 10 
2 More than 80 but less than 250 mg 7.5 
3 250 mg or more 5 
 
Friability Test 
 Weighed amount of 20 dedusted tablets were subjected to rotating drum of 
friability test apparatus. The drum rotated at a speed of 25 rpm. The apparatus was 
operated for 4 minutes and reweighed the tablets. Friability was calculated by the 
following formula. 
 
01 00 W WF
W
− 
=   
 
 F = Friability, W = Final weight, Wo = Initial weight 
 The result are give in table no. Results given in Table No.25,26 . 
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Hardness Test 
 The hardness of tablet was carried out by using Monsanto type hardness tester. 
The hardness of the tablet kg / cm² was measured. The result are give in table no. Results 
given in Table No 25,26.. 
Assay of the tablets ( UV spectrophotometer method ) 
 Ten tablets from the batch were weighed and powdered . power equivalent to 
the average weight of the tablet was accurately weighed and transferred into a 100 ml 
volumetric flask and dissolved in a suitable quantity of the 0.1 N HCL. The solution was 
made up to the mark and mixed well. A portion of the sample was filtered and analyzed 
by a UV spectrophotometer( double beam 1700 shimadzu, japan) at 263 nm. 
Assay (HPLC method) 
 Determined by liquid chromatography method 
Test solution: a freshly prepared 0.1 percent w/v solution of the substance under 
examination in phosphate buffer pH 5 
Reference  solution:  a  freshly prepared  0.1  percent  w/v  solution  of  cefadroxil   RS  
in phosphate buffer pH 5 
Chromatography system 
 A stainless steel column 25 cm × 4mm, packed with octadecylsilyl silica gel (30 
to 10 µm)  
 Mobile phase: a mixture of 96 volumes of phosphate buffer pH 5 and volume of 
acetonitrile,  
 Flow rate 1.5 ml per minute,  
 Spectrophotometer se at 230 nm,  
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 A 20µl loop injector.  
 Inject the reference solution. The test is not valid unless th e relative standard 
deviation for replicate injections is not more 2.0 percent. Refer table-27, 28  
Assay preparation  
 Weigh and finely powder NLT 10 tablets. transfer an accurately weighed 
portion of the powder, equivalent to about 200 mg of cefadroxil, to a 200 ml volumetric 
flask, dilute with pH 5 buffer to volume, and stir by mechanical means for 5 minutes. 
Use this solution on the day prepared. calculate the quantity in mg, of C16 H 17 N3 05 S in 
the portion of tablets taken by the formula.  
0.2 CE r u/ r s  
                  Avg. wt of the tablet  × amount  equivalent to be taken 
Sample to be taken =                                              
      Label claim 
 
    Average sample area ×standard weight × purity×  
                                    avg.wt of the tablet × 1000 
Amount of the tablet = 
      Standard area × sample area 
 
 
Preparation of Dissolution Medium pH 1.2 
 Placed 76.5 ml of the of concentrated hydrochloric acid in 823.5 ml of distilled 
water. 
Dissolution Study 
 Medium :  900 ml of 0.1 N hydrochloric acid. pH 1.2 
 Apparatus :  USP (paddle) 
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 Speed :  50 rpm 
 Time : 0.5,1,2,3,  4,5,6,7,8……24 hours 
 Temperature :  37C ± 0.5 C 
  λ :  263 nm 
 Perform the test on six tablets place one tablet in each dissolution vessel 
containing 900 ml of of 0.1 M hydrochloric acid (pH 1.2). Maintained at 370C ± 0.50C. 
At specified time withdrawn required amount of sample and take absorbance and 
calculate percentage release. Results were illustrated in tables. Results given in Table No. 
.29-38 
Floating property study 
 The time taken for dosage form to emerge on surface of medium called 
buoyancy lag time (BLT). Duration of time by which the dosage form constantly emerge 
on surface of medium called Total floating time (TFT). 
 Tablets were placed in a 400 ml flask of pH 1.2, time needed to go upward and 
float on surface of the liquid and floating duration were determined. Results given in 
Table No. 39 & 40 
Dertermination of Swelling Index  
 The Swelling Index of the tablets was determined in gastric fluid (0.1 N)at 
room temperature. The swelling property of the formulation was determined by various 
techniques. The water uptake study of the tablet was done using USP dissolution 
apparatus II. The medium used was gastric fluid(0.1 N),900 ml, rotated at 50 rpm. The 
medium was maintained at 37±0.5  C throughout the study. After selected time 
intervals, the tablets were withdrawn, blotted to remove excess water, and weighed. The 
swelling characteristics of the tablets were expressed as, Results given in Table No. 
41&.42 
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                 Weight of the swollen tablet- initial weight of the tablet 
Swelling  Index  = 
                                                            initial weight of the tablet 
Kinetics of Drug Release 
 The order of drug release can be assessed by graphical treatment of drug 
release data. 
 A plot of % drug remaining versus time would be linear if the drug release 
follows zero order (ie. Concentration independent release). 
 A plot of log of % remaining drug versus time would be linear, if the drug 
release follows first order (ie. concentration dependent release) 
 The linear equation for zero order drug release plot is: 
 Ct = C0 – Kt 
Where,  Ct = concentration remaining at time t, 
 Co = original concentration, 
 t = time, 
 K = release rate 
The linear equation for first order release plot is 
 
0loglog
2.303
C KtC =
 
 A matrix device as the name implies, consists of drug dispersed 
homogeneously through out a polymer matrix. 
 In this model, drug in the out side layer exposed to the bathing solution is 
dissolved first and than diffuses out of the matrix. This process continues with the 
interface between the bathing solution and the solid drug moving towards the interior. 
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Obviously, for this system to be diffusion controlled, the rate of dissolution of drug 
particles with in the matrix must be much faster than the diffusion rate of dissolved drug 
leaving the matrix. Deviation of the mathematical model to describe this system involves 
the following assumptions. 
1) A pseudo study state is maintained during drug release.  
2) The diameter of the drug particles is less than the average distance of drug 
diffusion through the matrix.  
3) The bathing solution provides sink conditions at all times and  
4) The diffusion coefficient of drug in the matrix remains constant  
(ie. no change occurs in the characteristics of the polymer matrix).  
 Hydrophilic matrix tablets contain a water swellable polymer. On contact with 
gastric juices the tablet surface gels, impeding further liquid penetration into the tablet 
core and providing a rate controlling layer. Dissolution occurs at the gel core interface 
and drug diffuse out through the gelled layer. 
 Drug release is controlled by penetration of water through a gel layer produced 
by hydration of the polymer and diffusion of drug through the swollen, hydrated matrix, 
in addition to erosion. The extent to which diffusion or erosion controls release depends 
on the polymer ration. 
 Mechanism of release from erodable matrix has been described by Hopfenberg. 
A simple expression describing release from erodable is 
 
1/ 3
1 1Mt Kt
M
 
− = − 
 
 
Where, Mt = mass of drug release at time t,   
 M = mass release at the infinite time,  
 K = rate of erosion,    
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 t = time    
 Thus a plot of [1 – Mt / M]1/3 versus the time will be linear. If the release of 
drug from the matrix is erosion controlled. 
 In order to ascertain whether the drug release occurs by diffusion or erosion, 
the drug release data was subjected to following modes of data treatments. 
1) Amount of drug release versus square root of time (Higuchi Plot).  
2) [1 – Mt / M]1/3 versus time.  
 The results are discussed in table 43-46  
Accelerated stability studies 
Stability 
 Stability is officially defined as the time lapse during which the drug product 
retains the same property and characteristics that it possessed at the time of manufacture. 
This process begins at early development phases. 
 Instability in modern formulation is often undetectable only after considerable 
storage period under normal conditions. To assess the stability of a formulated product it 
is usual to expose it to high stress conditions to enhance deterioration and therefore the 
time required for testing is reduced. Common high stresses are temperature and 
humidity. This will eliminate unsatisfactory formulation. 
Strategy of stability testing 
 The study of drug decomposition kinetics  
 The development of stable dosage form  
 Establishment of expiration date for commercially available drug product is 
some of the needs of stability testing  
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 Data from which study should be provided on at least 3 primary batches of 
the drug product  
 The batches should be manufactured to a minimum of pilot scale  
 Important point of view of the safety of the paient, patient relieves a uniform 
dose of drug throughout the shelf life of the product.  
Table-15  : The Stability Storage Condition 
SI.NO STUDY STORAGE CONDITION 
MINIMUM 
PERIOD 
1 Long-term 25ºC ± 2ºC 12 months 
2 Intermediate 30ºC ± 2ºC 6 months 
3 Accelerated 40ºC ± 2ºC 6 months 
  75% ± 5% RH  
                           
PROCEDURE 
 Selected batches were placed in a high density polyethylene container, blister 
pack, strip pack etc. They are kept in stability chamber maintained at 40ºc and 75% 
RH.The stability studies were carried out for a period of one month. The tablets were 
tested and checked at regular intervals for changes in physical appearance and percentage 
of drug content. The results are discussed in Table 47-50. 
 
 
 
FT-IR STUDIES 
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Figure16  Ft-Ir Study For Cefadroxil 
 
 
 
Table-16  Interpretation (Cefadroxil) 
 
 
S.NO WAVE NUMBER Interpretation 
   
1 1117.44 C-S 
2 1236.79 C-O-C(asymmetric) 
3 1568.72 ЅNH (amide) 
   
4 1759.06 COOH 
5 2830.90 Csp³H 
6 3028.33 Csp²H 
7 3197.46, 3412.71 OH Stretch 
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Figure-17 FT-IR Study For Citric Acid 
 
 
Table-17 Interpretation (Citric Acid) 
 
 
S.NO WAVE NUMBER INTERPRETATION 
1 1728.48 COOH 
2 3396.72, 3294.25, OH Stretch 
 
3197.77 
 
                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-18 FT-IR Study For HPMC 
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Table-18 Interpretation (Hpmc) 
 
S. NO WAVE NUMBER INTERPRETATION 
1 1360.30 C-O-C 
2 1599.04 C = O 
3 2932.30 CH Stretching 
4 3432.99 OH stretching 
 
 
 
 
Figure-19 FT-IR Study for SCMC 
 
 
Table-19 Interpretation (SCMC) 
 
S.NO WAVE NUMBER INTERPRETATION 
1 1348.19 C=0 
2 1599.94 OCH3 
3 2918.04 CH Stretch 
4 3426.09 OH Stretch 
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Figure-20 FT-Ir Study  For Polymer And Drug 
 
 
Table-20 Interretation (Drug and Polymer) 
 
S.NO WAVE NUMBER ASSIGNMENT 
1 1222.16 C-O-C 
2 1617.36 SNH amide 
3 1736.35 COOH 
4 3003.90 Csp³H 
5 3154.54, 3460.72 OH Stretch 
 
Table-21 standard Curve  Standard Curve Of Cefadroxil In Distilled Water 
 
SINo. 
Concentration 
(µg/ml) Absorbance at 263 nm 
 
 
 
1. 5 0.0911 
 
2. 10 0.1926 
 
3. 15 0.2709 
 
4. 20 0.3521 
 
5. 25 0.4479 
 
6. 30 0.5446 
 
7. 35 0.6656 
 
8. 40 0.7306 
 
 a = 0.0370  
 
 b = 0.0184  
 
 r = 0.9985  
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Figure-21 Standard Curve of Cefadroxil (distilled Water) 
 
Table-22 Standard Curve Of Cefadroxil in 0.1 N HCL 
 
 
SI 
No. Concentration (µgl ml) Absorbance at 263 nm 
 
 
1. 5 0.0710  
2. 10 0.1646  
3. 15 0.2662  
4. 20 0.3727  
5. 25 0.4613  
6. 30 0.5486  
7. 35 0.6536  
8. 40 0.7621  
 
a = - 0.02776 
b = 0.01956
r = 0.9996
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Figure-22 Standard curve of cefadroxil (0.1N) HCL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure -23 & 24 Predicting the absorption maxima in two solvent( distilled water & 
0.1N HCL) 
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Finding Absorption maxima 
 
The Absorption maxima was found in two solvents. 
 
 
1)Distilled water - 262.5
2)0.1 N HCl - 263.3
 
 
 
Evaluation of Powder Blend Ready for Compression 
 The powder blend ready for compression was evaluated for its physicochemical 
parameters. The various Physical parameters are shown in table 15 given below. 
 
CEFADROXIL STRENGTH 125 mg 
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Table-23 Evaluation of powder blend ready for compression 
 
 
FORMULATION 
CODE 
BULK 
DENSITY 
TAPPED 
DENSITY 
CARR’S 
INDEX 
HAUSNER’S 
RATIO 
ANGLE 
OF 
REPOSE 
F1 0.35 0.44 12.00 0.88 24.70 º 
F2 0.32 0.38 14.47 1.18 20.80 º 
F3 0.34 0.38 11.00 1.11 21.80 º 
F4 0.33 0.37 12.38 1.14 24.22 º 
F5 0.40 0.46 12.24 0.87 25.25 º 
 
 
 
CEFADROXIL STRENGTH 250 mg 
 
Table-24 Evaluation of powder blend ready for compression 
 
 
 
FORMULATION 
CODE 
BULK 
DENSITY 
TAPPED 
DENSITY 
CARR’S 
INDEX 
HAUSNER’S 
RATIO 
ANGLE 
OF 
REPOSE 
F6 0.41 0.46 10.57 1.12 22.78º 
F7 0.37 0.43 13.48 0.86 23.70º 
F8 0.36 0.41 11.54 1.13 27.02º 
F9 0.35 0.42 13.07 1.14 24.22º 
F10 0.45 0.54 15.96 1.18 26.56º 
 
 
 
9.6 PHYSICAL EVALUATION OF TABLET  
9.6.1  Physico chemical parameters:  
a)  Uniformity of weight test: 
 
 
 Weight variation test was performed for 20 tablets from each batch and Results 
are showed in table 24 
 
b)  Hardness 
 
 
 The average hardness of three tablets of from each batch and results are shown 
in table 24 
 
 
c) Friability  
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% Friability was determined for 20 tablets from each batch and was found to 
lie within limited range of less than 1%. So all the tablets comply with the test for 
friability. Results are shown in table 24  
 
Table-25 Cefadroxil Strength 125 mg 
 
Formulation 
code 
Average 
weight of 
tablet (mg) ± 
limit 
Average 
Hardness * 
2 (Kg/cm ) 
% 
Friability* 
 
 
 
 
 
 
 
F1 0.4177 5.43 0.72  
F2 0.4612 5.76 0.87  
F3 0.5099 5.46 0.48  
F4 0.5522 5.73 0.53  
F5 0.6162 5.33 0.47  
 
Table-26 Cefadroxil Strength 250 mg 
 
Formulation 
code 
Average 
weight of 
tablet (mg) ± 
limit 
Average 
Hardness * 
2 
(Kg/cm ) 
% 
Friability* 
F6 0.6172 5.64 0.65 
F7 0.6629 5.76 0.86 
F8 0.7115 5.40 0.98 
F9 0.7615 5.36 0.79 
F10 0.8125 5.30 0.61 
 
 
D)  Content uniformity (uv spectrophotometeric method) 
 The percentage drug content of the different formulations is as shown in table 
20. The percentage drug content of all formulation batches was found to be in the range 
of IP limits. Drug content was found to be uniform with all formulations. 
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Table-27cefadroxil Strength 125 mg 
Formulation 
code 
Amount of 
cefadroxil 
(mg/tablet) 
Percentage drug 
content 
F1 115.10 92.10 
F2 123.30 98.64 
F3 120.05 96.04 
F4 122.08 97.66 
F5 123.64 98.02 
 
Table-28 Cefadroxil Strength 250mg 
Formulation 
code 
Amount of 
cefadroxil 
(mg/tablet) 
Percentage drug 
content 
 
 
 
 
 
 
F6 226,0 90.78 
 
 
F7 246.70 98.68 
 
 
F8 244.01 97.60 
 
 
F9 247.01 98.80 
 
 
F10 244.60 97.84 
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Figure- 25,26 & 27 Assay of the Tablet by Hplc Method (F5 & F10) 
Standard: 
Area –33189989 
CEFADROXIL STRENGTH 125 mg (F5) 
Area-29968719 
CEFADROXIL STRENGTH 250 mg (F10) 
Area-27668103 
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CALCULATION 
Avg. Wt of the tablet × equi. amount to be
    
Sample to be taken  
    
 
    
    
Amount Of The Tablets 
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  taken 
= 
  label claim 
= (0.6679/0.1250)*0.1  
= 0.539 gm  
 Avg. Sample Area × Standard Weight× 
 Purity × Avg. wt of the tablet ×1000
 = 
  Avg. Standard area ×Sample 
         29968719 × 0.1199 × 97.25 × 0.6267 × 1000
= 
            33189989 × 0.5399 × 100
=  122.21mg.(97.76%) 
 
120 
 
 
wt 
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Sample to be taken 
 Avg. Wt of the tablet × equi. Amount to be taken
=   
    
= (0.821/0.250) × 0.1 
= 0.3275 gm  
 2766103× 0.119× 97.25× 0.821× 1000
= 
       33189989 × 0.3275 × 100 = 243.67 gm (97.46%)
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Label claim 
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CEFADROXIL STRENGTH 125 mg 
Dissolution study  
Dissolution study of F1 (TABLE-29) Medium: 0.1 N HCL  
Label claim: 115.1 mg  
TIME 
( hrs) 
ABSORBANCE * 
(nm) 
CONCENTRATION 
(g/ml) 
AMOUNT 
RELEASED 
(mg) 
% 
AMOUNT 
RELEASED 
 
 
 
 
 
2 1.8075 93.67 84.30 73.24  
4 2.4210 125.19 112.67 97.89  
6      
8      
10      
12      
14      
16      
18      
20      
22      
24      
 
 
 
 
 
 
 
Figure-28 Dissolution Profile (125 mg) 
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Dissolution study of F2 
Medium: 0.1 N HCL 
Label claim: 123.3 mg 
TABLE-30 
TIME ABSORBANCE 
* 
(nm) 
CONCENTRATION 
(µg/ml) 
AMOUNT 
RELEASED 
(mg) 
% 
AMOUNT 
RELEASED ( hrs) 
2 0.9227 48.58 43.73 35.46 
4 1.8255 94.74 88.26 69.14 
6 2.4996 129.20 116.28 94.30 
8 2.6221 135.47 121.92 98.88 
10     
12     
14     
16     
18     
20     
22     
24     
 
 
Figure-29 
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Dissolution study of F3 Medium: 0.1 N HCL Label claim: 120.08 mg 
Table-31 
TIME 
( hrs) 
ABSORBANCE * 
(nm) 
CONCENTRATION 
(g/ml) 
AMOUNT 
RELEASED 
(mg) 
% 
AMOUNT 
RELEASED 
 
 
 
2 0.9224 48.57 43.71 36.42  
4 1.3214 68.97 62.07 51.72  
6 1.7791 92.37 83.13 69.27  
8 2.1431 110.98 99.88 83.23  
10 2.3912 23.66 111.30 92.36  
12 2.4795 128.18 115.36 96.01  
14 2.5095 129.71 116.74 97.22  
16      
18      
20      
22      
24      
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Dissolution study of F4 
Medium: 0.1 N HCL 
Label claim: 122.08 mg 
Table-32 
TIME 
( hrs) 
ABSORBANCE 
* 
(nm) 
CONCENTRATION 
(g/ml) 
AMOUNT 
RELEASED 
(mg) 
% 
AMOUNT 
RELEASED 
2 0.4284 23.31 20.98 17.20 
4 0.8499 44.86 40.38 33.09 
6 1.2451 65.07 58.56 48.00 
8 1.6692 86.75 78.07 63.99 
10 2.0014 103.73 93.36 76.41 
12 2.2341 115.63 104.07 85.30 
14 2.4562 126.98 114.28 93.68 
16 2.5402 131.28 118.15 96.84 
18 2.5861 133.62 120.26 98.57 
20     
22     
24     
 
 
Figure-31 
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8.  SUMMARY  
In present work, attempts have been made to formulate floating matrix 
extended release tablets of cefadroxil, by using different ratio of hydrophilic 
polymer HPMC K100M and sodium carboxy methyl cellulose and sodium 
bicarbonate as a gas generating agent. Cefadroxil is a acid stable broad-spectrum 
antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative 
bacterial infections. It is a bactericidal antibiotic. The floating Matrix tablets were 
prepared by wet granulation technique. Cefadroxil meets all the ideal characteristics 
to formulate in the form of extended release drug delivery system. 
Under preformulation study, the organoleptic properties were complied 
with the IP specification. Physical properties such as bulk density and tapped density 
were more in case of granules ready for compression than that on cefadroxil raw 
powder. melting point determination were given the information about the purity of 
the drug powder respectively. the result of angle of repose of drug powder showed 
the poor flow properties. 
Solution properties i.e pH of the solution and solubility were evaluated, 
results were complied with the pharmacopoeial specification. 
All the formulations were evaluated on the basis of pharmacopoeial 
specifications. Shape of the tablets was round standard concave hardness, weight 
variation, floating time study, dissolution test were carried out. 
Assay of cefadroxil was carried out by both uv spectrophotometric method 
and hplc method. 
 Assay (UV METHOD) was carried out for F5 and F10 was found to be 
98.02% and 97.84% 
 Assay (HPLC METHOD) was carried out for F5 mg) and F10 was found 
to be 97.76% and 97.46% 
Summary and Conclusion 
Department of Pharmaceutics, Avpc 
128 
 
Infra Red spectrum of cefadoxil matches with the standard spectrum as 
well in tablet there are no any additional peak formation. 
Stability studies of the selected formulated tablets were carried out by 
keeping the tablets at room temperature and at 40 oC + 2 oC/ 75 + 5 % RH (stability 
chamber) for 30 days. All the parameters were within the limit after 30 days. 
 The mechanism of drug release form matrix tablets were combination of 
swelling diffusion and erosion in all cases. 
 The release rate of cefadroxil matrix floating tablets followed near mixed 
order kinetics, which was obtained by plotting, a graph of cumulative percentage 
drug release Vs time. 
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    CONCLUSION 
In the present study attempts were made to formulate two different 
strength( 125mg & 250 mg) of cefadroxil floating matrix extended release tablet, by 
wet granulation. 
The In Vitro study, shows formulation No.5 & 10 were well suited to be 
extended release formulation due to floating up to 24 hrs. 
Formulation F5 & F10 was found 0074o obey nearly zero to zero order 
drug release governed by diffusion through swollen matrix, showing anlomous 
diffusion or non fickian transport. 
Infrared spectrum of tablet reveals that there is no interaction of the 
polymer and tablet matrix with cefadroxil 
Stability study is passed as per specification. 
Further in-vivo and continuation of stability study are recommended. 
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